Pressure BioSciences (PBIO) 10-K 22 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 17, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	830,656
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 10,076,490
Entity Common Stock, Shares Outstanding		31,639,839
Trading Symbol	PBIO
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 138,363	$ 116,783
Accounts receivable, net of $28,169 reserve at December 31, 2016 and $0 at December 31, 2015	281,320	113,256
Inventories, net of $20,000 reserve at December 31, 2016 and $50,000 at December 31, 2015	905,284	1,038,371
Prepaid income taxes	7,405	7,381
Prepaid expenses and other current assets	258,103	213,926
Total current assets	1,590,475	1,489,717
Investment in available-for-sale equity securities	25,865	294,522
Property and equipment, net	9,413	20,149
TOTAL ASSETS	1,625,753	1,804,388
CURRENT LIABILITIES
Accounts payable	407,249	941,389
Accrued employee compensation	249,596	176,009
Accrued professional fees and other	956,884	821,088
Deferred revenue	159,654	140,878
Revolving note payable, net of unamortized debt discounts of $637,030 and $0, respectively	612,970
Convertible debt, net of unamortized discounts of $2,235,839 and $0, respectively	4,005,702	100,000
Other debt, net of unamortized discounts of $380 and $3,041, respectively	238,157	151,628
Warrant derivative liabilities	1,685,108	3,295,976
Conversion option derivative liabilities	951,059	3,940,791
Total current liabilities	9,266,379	9,567,759
LONG TERM LIABILITIES
Related party convertible debt, net of unamortized debt discounts of $165,611 and $0, respectively	125,523
Convertible debt, net of unamortized discounts of $740,628 and $5,223,658, respectively	529,742	177,342
Deferred revenue	87,527	36,935
TOTAL LIABILITIES	10,009,171	9,782,036
STOCKHOLDERS' DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 30,999,839 and 23,004,898 shares issued and outstanding on December 31, 2016 and 2015, respectively	309,998	230,050
Warrants to acquire common stock	6,325,102	5,416,681
Additional paid-in capital	27,244,600	26,036,733
Accumulated other comprehensive loss		(105,025)
Accumulated deficit	(42,264,190)	(39,557,206)
Total stockholders' deficit	(8,383,418)	(7,977,648)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,625,753	1,804,388
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	866	866
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	35	36
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 68	$ 114

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable, reserve	$ 28,169	$ 0
Inventories reserve	20,000	50,000
Revolving note payable, unamortized discount	637,030	0
Convertible debt, current unamortized discounts	2,235,839	0
Other debt, unamortized discounts net	380	3,041
Convertible debt related party unamortized debt discount net	165,611	0
Convertible debt, non current unamortized discounts	$ 740,628	$ 5,223,658
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	1,000,000	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,999,839	23,004,898
Common stock, shares outstanding	30,999,839	23,004,898
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ .01	$ .01
Convertible preferred stock, authorized	850	850
Convertible preferred stock, shares issued	300	300
Convertible preferred stock, shares outstanding	300	300
Convertible preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	240,000	240,000
Convertible preferred stock, shares issued	86,570	86,570
Convertible preferred stock, shares outstanding	86,570	86,570
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	21	21
Convertible preferred stock, shares issued	21	21
Convertible preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	6,250	6,250
Convertible preferred stock, shares issued	3,521	3,546
Convertible preferred stock, shares outstanding	3,521	3,546
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	15,000	15,000
Convertible preferred stock, shares issued	6,816	11,416
Convertible preferred stock, shares outstanding	6,816	11,416

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Products, services, other	$ 1,794,749	$ 1,409,991
Grant revenue	181,738	387,700
Total revenue	1,976,487	1,797,691
Costs and expenses:
Cost of products and services	834,012	609,054
Research and development	1,183,011	1,105,295
Selling and marketing	872,365	745,574
General and administrative	2,822,752	2,902,950
Total operating costs and expenses	5,712,140	5,362,873
Operating loss	(3,735,653)	(3,565,182)
Other (expense) income:
Interest expense	(4,501,186)	(4,146,416)
Other expense	(1,112)	(36,879)
Impairment loss on investment	(373,682)
Gain on extinguishment of embedded derivative liabilities		2,555,180
Change in fair value of derivative liabilities	5,904,649	(2,222,001)
Total other (expense) income	1,028,669	(3,850,116)
Net loss	(2,706,984)	(7,415,298)
Accrued dividends on convertible preferred stock		(23,194)
Net loss applicable to common shareholders	$ (2,706,984)	$ (7,438,492)
Net loss per share attributable to common stockholders - basic and diluted	$ (0.10)	$ (0.36)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	27,339,362	20,726,205

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Comprehensive Loss
Net loss	$ (2,706,984)	$ (7,415,298)
Other comprehensive loss
Unrealized loss on marketable securities	105,025	(105,025)
Comprehensive loss	$ (2,601,959)	$ (7,520,323)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Series D Preferred Stock [Member]	Series G Preferred Stock [Member]	Series H Preferred Stock [Member]	Series H(2) Preferred Stock [Member]	Series J Preferred Stock [Member]	Series K Preferred Stock [Member]	Common Stock [Member]	Stock Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2014	$ 3	$ 866	$ 100		$ 36	$ 114	$ 186,734	$ 5,253,566	$ 24,617,564		$ (32,118,714)	$ (2,059,731)
Balance, shares at Dec. 31, 2014	300	86,570	10,000	21	3,546	11,416	18,673,390
Stock-based compensation									208,989			208,989
Issuance of common stock for services							$ 17,551		439,479			$ 457,030
Issuance of common stock for services, shares							1,755,091					1,755,091
Warrant revaluation								69,627				$ 69,627
Stock exchange with Everest Investments							$ 10,000		389,547			399,547
Stock exchange with Everest Investments, shares							1,000,000
Issuance of warrants for services								93,488				93,488
Conversion of debt and interest for commons stock							$ 15,765		381,154			$ 396,919
Conversion of debt and interest for commons stock, shares							1,576,417					(382,054)
Dividends earned											(23,194)	$ (23,194)
Unrealized loss on investments, net of tax										(105,025)		(105,025)
Stock issued with debt												$ 58,919
Stock issued with debt, shares												235,676
Net loss											(7,415,298)	$ (7,415,298)
Balance at Dec. 31, 2015	$ 3	$ 866	$ 100		$ 36	$ 114	$ 230,050	5,416,681	26,036,733	(105,025)	(39,557,206)	(7,977,648)
Balance, shares at Dec. 31, 2015	300	86,570	10,000	21	3,546	11,416	23,004,898
Stock-based compensation									379,964			379,964
Issuance of common stock for services							$ 7,550		325,146			332,696
Issuance of common stock for services, shares							755,000
Issuance of warrants for services								84,735				84,735
Conversion of debt and interest for commons stock							$ 4,208		113,629			$ 117,837
Conversion of debt and interest for commons stock, shares							420,849					(100,000)
Dividends earned												$ (23,194)
Unrealized loss on investments, net of tax										105,025		105,025
Warrant exercise							$ 230	(11,100)	10,870
Warrant exercise, shares							22,996
Conversion of Series J convertible preferred stock					$ (1)		$ 250		(249)
Conversion of Series J convertible preferred stock, shares					(25)		25,000
Conversion of Series K convertible preferred stock						$ (46)	$ 46,000		(45,954)
Conversion of Series K convertible preferred stock, shares						(4,600)	4,600,000
Issuance of common stock for dividends paid-in-kind							$ 2,485		61,370			63,855
Issuance of common stock for dividends paid-in-kind, shares							248,547
Common stock offering							$ 15,250	315,301	279,449			610,000
Common stock offering, shares							1,525,000
Offering costs for issuance of common stock									(79,035)			(79,035)
Stock issued with debt							$ 3,975		141,956			145,931
Stock issued with debt, shares							397,549
Warrants issued with debt								519,485				519,485
Beneficial conversion feature									20,721			20,721
Net loss											(2,706,984)	(2,706,984)
Balance at Dec. 31, 2016	$ 3	$ 866	$ 100		$ 35	$ 68	$ 309,998	$ 6,325,102	$ 27,244,600		$ (42,264,190)	$ (8,383,418)
Balance, shares at Dec. 31, 2016	300	86,570	10,000	21	3,521	6,816	30,999,839

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,706,984)	$ (7,415,298)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	17,939	25,288
Provision for bad debts	28,169
Accretion of interest and amortization of debt discount	4,003,485	2,989,765
Penalty interest added to debt principal	41,200
Gain on settlement of debt	(5,044)
Stock-based compensation expense	379,964	208,989
Warrant expense	84,735	163,115
Amortization of third party fees paid in common stock	332,696	457,030
Impairment loss on investment	373,682
Gain on extinguishment of embedded derivative liabilities		(2,555,180)
Change in fair value of derivative liabilities	(5,904,649)	2,222,001
Changes in operating assets and liabilities:
Accounts receivable	(196,233)	158,766
Inventories	133,087	(187,820)
Prepaid expenses and other assets	(44,201)	(15,722)
Accounts payable	(534,140)	(94,392)
Accrued employee compensation	73,587	18,662
Deferred revenue and other accrued expenses	116,856	205,050
Net cash used in operating activities	(3,805,851)	(3,819,746)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(7,203)	(9,412)
Net cash used in investing activities	(7,203)	(9,412)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from related party debt	116,667	6,300
Payment of related party debt	(20,000)	(12,300)
Net proceeds from revolving note payable	1,133,500
Net proceeds from convertible debt	2,105,420	5,558,537
Payments on convertible debt	(107,000)	(2,653,990)
Net proceeds from non-convertible debt	1,022,784	1,257,418
Payments on non-convertible debt	(947,702)	(587,949)
Net proceeds from the issuance of common stock	530,965
Payment of accrued prepayment penalty		(96,023)
Net cash provided by financing activities	3,834,634	3,471,993
NET INCREASE (DECREASE) IN CASH	21,580	(357,165)
CASH AT BEGINNING OF YEAR	116,783	473,948
CASH AT END OF PERIOD	138,363	116,783
SUPPLEMENTAL INFORMATION
Interest paid in cash	260,979	1,072,900
Income taxes paid in cash
NON CASH TRANSACTIONS:
Shares issued for conversion of debt and interest	117,837	396,919
Cashless exercise of warrants	11,100
Discount due to beneficial conversion feature	20,721
Discount due to warrants issued with debt	519,485
Common stock issued with debt	104,731
Common stock issued to settle non-convertible debt	41,200
Conversion of preferred stock and accrued dividends into common stock	63,902
Accrued dividends on preferred stock		23,194
Issuance of common stock for investment in available-for-sale equity securities		399,547
Unrealized loss from available-for-sale equity securities		105,025
Debt discount from derivative liability	1,304,049	6,819,730
Debt discount related to accrual of one-time interest	170,000
Extension fees added to principal		84,000
Prepayment penalty and accrued interest enrolled into debt principal		48,950
Reversal of accumulated other comprehensive income to impairment loss on investment	$ 105,025

Business Overview

Business Overview	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	(1) Business Overview Pressure Biosciences, Inc. (“we”, “our”, “the Company”) is focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming, and in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking, the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (35,000 psi or greater) to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels - at controlled temperatures and specific time intervals - to rapidly and repeatedly control the interactions of bio-molecules, such as DNA, RNA, proteins, lipids, and small molecules. Our laboratory instrument, the Barocycler®®, and our internally developed consumables product line, including PULSE® (Pressure Used to Lyse Samples for Extraction) Tubes, other processing tubes, and application specific kits (which include consumable products and reagents) together make up our PCT Sample Preparation System, or PCT SPS. In 2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating activities and we cannot reasonably predict when operations will commence. Therefore, we do not have control of the subsidiary and did not consolidate in our financial statements. PBI Europe did not have any operations in 2016 or in 2015.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	(2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of December 31, 2016, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Notes 8 and 9, completed debt financing subsequent to December 31, 2016. We have financing efforts in place to continue to raise cash through debt and equity offerings. Management has developed a plan to continue operations. This plan includes obtaining equity or debt financing. During the year ended December 31, 2016 we received $4,378,371 net proceeds, in additional convertible and non-convertible debt. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. We need substantial additional capital to fund normal operations in future periods. In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects. These financial statements do not include any adjustments that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation. ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. iii. Revenue Recognition Revenue is recognized when realized or when realizable and earned when all the following criteria have been met: persuasive evidence of an arrangement exists; goods were shipped, delivery of service has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. Our current instruments, the Barocycler NEP3229 and NEP2320, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon shipment of the unit, or in the case where the customer requests installation and training, the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue. The Company applies ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. The Company currently records revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when qualifying expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and the Company’s service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying deliverables. Revenue from service contracts is recorded ratably over the length of the contract. Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”) iv. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents. v. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life. vi. Inventories Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: 2016 2015 Raw materials $ 326,228 $ 310,367 Finished goods 599,056 778,004 Inventory reserve (20,000 ) (50,000 ) Total $ 905,284 $ 1,038,371 vii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets. viii. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over sixteen years. We perform an annual review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2016 and 2015, the outstanding balance for intangible assets is zero. ix. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment x. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2016 and 2015, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2016 2015 Top Five Customers 29 % 38 % Federal Agencies 3 % 23 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2016 2015 Top Five Customers 82 % 93 % Federal Agencies 1 % 1 % Investment in Available-For-Sale Equity Securities As of December 31, 2016, we held 601,500 shares of common stock of Everest, a Polish publicly traded company listed on the Warsaw Stock Exchange. We exchanged 1,000,000 shares of our common stock for the 601,500 shares from Everest. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities” xi. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: 2016 2015 Numerator: Net loss $ (2,706,984 ) $ (7,415,298 ) Preferred dividends accrued - (23,194 ) Net loss applicable to common shareholders $ (2,706,984 ) $ (7,438,492 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 27,339,362 20,726,205 Loss per common share - basic and diluted $ (0.10 ) $ (0.36 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2016 2015 Stock options 5,269,250 5,571,250 Convertible debt 26,733,955 19,689,286 Common stock warrants 26,459,695 29,227,664 Convertible preferred stock: Series D Convertible Preferred 750,000 750,000 Series G Convertible Preferred 865,700 865,700 Series H Convertible Preferred 1,000,000 1,000,000 Series H2 Convertible Preferred 2,100,000 2,100,000 Series J Convertible Preferred 3,521,000 3,546,000 Series K Convertible Preferred 6,816,000 11,416,000 73,515,600 74,165,900 xii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2016 and 2015, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2016 and 2015. xiii. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee awards are accounted for under ASC 718 where the awards are valued at grant date. Awards given to nonemployees are accounted for under ASC 505 where the awards are valued at earlier of commitment date or completion of services. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2015: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs) 6.0 (yrs) Expected volatility 116.32%-141.15 % 116.32%-141.15 % Risk-free interest rate 0.65%-2.54 % 0.65%-2.54 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 % We recognized stock-based compensation expense of $379,964 and $208,989 for the years ended December 31, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: 2016 2015 Research and development $ 65,500 $ 50,617 Selling and marketing 42,315 32,704 General and administrative 272,149 125,668 Total stock-based compensation expense $ 379,964 $ 208,989 During the years ended December 31, 2016 and 2015, the total fair value of stock options awarded was $0 and $598,582, respectively. As of December 31, 2016, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $369,224. The non-cash, stock based compensation expense associated with the vesting of these options will be $212,957 in 2017 and $156,267 in 2018. xiv. Advertising Advertising costs are expensed as incurred. We incurred $19,125 in 2016 and $12,291 in 2015 for advertising. xv. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value. xvi. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1 and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy. The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2016 and December 31, 2015. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2016 using: December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 25,865 25,865 - - Total Financial Assets $ 25,865 $ 25,865 $ - $ - December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 23,313 - - $ 23,313 Warrants Issued with Convertible Debt 1,661,795 - - 1,661,795 Conversion Option Derivative Liabilities 951,059 - - 951,059 Total Derivatives $ 2,636,167 $ - $ - $ 2,636,167 Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 294,522 294,522 - - Total Financial Assets $ 294,522 $ 294,522 $ - $ - December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 - - $ 173,526 Warrants Issued with Convertible Debt 3,122,450 - - 3,122,450 Conversion Option Derivative Liabilities 3,940,791 - - 3,940,791 Total Derivatives $ 7,236,767 $ - $ - $ 7,236,767 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2016 Issuance fair value Change in fair value December 31, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ - $ (150,213 ) $ 23,313 Warrants Issued with Convertible Debt 3,122,450 1,094,432 (2,555,087 ) 1,661,795 Conversion Option Derivative Liabilities 3,940,791 1,547,127 (4,536,859 ) 951,059 Total Derivatives $ 7,236,767 $ 2,641,559 $ (7,242,159 ) $ 2,636,167 January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ 13,651 $ - $ 173,526 Warrants Issued with Convertible Debt - 2,320,021 802,429 - 3,122,450 Conversion Option Derivative Liabilities 590,341 5,305,185 600,445 (2,555,180 ) 3,940,791 Total Derivatives $ 750,216 $ 7,625,206 $ 1,416,525 $ (2,555,180 ) $ 7,236,767 The issuance fair values for 2016 and 2015 include the “day 1” derivative losses on the conversion option derivative liabilities of $1,337,510 and $805,476, respectively, which are included in “change in fair value of derivative liabilities” in the consolidated statements of operations. The fair value of the derivative liabilities was determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2015 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 11.0 5.0 Expected volatility 104.5 % 104.9 % 83.5 % Risk-free interest rate 0.875 % 0.65 % 0.62 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.16 $ 0.02 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2015 and 2016 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 55.0-60.0 43.0-51.0 Expected volatility 118.3-120.1 % 136.3-141.6 % 110.0-116.0 % Risk-free interest rate 1.48-1.69 % 1.29-1.76 % 1.93 % Exercise price $ 0.40 $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$0.21 $ 0.30 $ 0.12-0.14 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2015 Conversion options revalued at December 31, 2016 Expected life (in months) 6.0-24.0 0-18.0 18-24 6.0-15.0 Expected volatility 104.2-153.8 % 86.9%-142.2 % 112.2-114.7 % 84.4-94.8 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 1.06 % 0.62-0.85 % Exercise price $ 0.10-$0.35 $ 0.10-$0.25 $ 0.28 $ 0.28 Fair value per conversion option $ 0.09-$0.28 $ 0.07-$0.26 $ 0.14-$0.33 $ 0.03-$0.06 xvii. Recently Issued Accounting Standards In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company early-adopted ASU 2015-03 as of the end of its Fiscal 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 resulted in the reclassification of approximately $888,000 unamortized debt issuance costs related to the Company’s Senior Notes (see Note 8) from other non-current assets to long-term debt within its consolidated balance sheets as of December 31, 2015. Other than this reclassification, the adoption of ASU 2015-03 and other new pronouncements that have been issued did not have an impact on the Company’s consolidated financial statements.

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment as of December 31, 2016 and 2015 consisted of the following components: December 31, 2016 2015 Laboratory and manufacturing equipment $ 226,326 $ 226,081 Office equipment 165,832 158,872 Leasehold improvements 8,117 8,117 PCT collaboration, demonstration and leased systems 461,858 461,858 Total property and equipment 862,133 854,928 Less accumulated depreciation (852,720 ) (834,779 ) Net book value $ 9,413 $ 20,149 Depreciation expense for the years ended December 31, 2016 and 2015 was $17,939 and $25,288, respectively.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement Plan	(5) Retirement Plan We provide all of our employees with the opportunity to participate in our retirement savings plan. Our retirement savings plan has been qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the plan through payroll deductions within statutory limitations and subject to any limitations included in the plan. During 2016 and 2015 we contributed $22,627 and $22,098, respectively, in the form of discretionary Company-matching contributions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(6) Income Taxes Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2016 and 2015, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2016 and 2015. Our tax returns for fiscal years 2013, 2014 and 2015 are open to examination. We did not record an income tax benefit or provision for the years ended December 31, 2016 and 2015. Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2016 and 2015 are as follows: 2016 2015 Current deferred taxes Inventories $ 7,856 $ 19,640 Accounts receivable allowance 17,253 - Other accruals 33,399 23,714 Less: valuation allowance (58,508 ) (43,354 ) Total current deferred tax assets $ - $ - Long term deferred taxes: Accelerated tax depreciation $ 14,582 $ 14,134 Non-cash, stock-based compensation, nonqualified 711,676 562,426 Impairment loss on investment 146,782 - Goodwill and intangibles - - Operating loss carry forwards and tax credits 13,561,012 12,028,900 Less: valuation allowance (14,434,052 ) (12,605,460 ) Total long term deferred tax assets (liabilities), net - - Total net deferred tax liabilities $ - $ - A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, a valuation allowance was established in 2016 and 2015 for the full amount of our deferred tax assets due to the uncertainty of realization. We believe based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2016. We have net operating loss carry-forwards for federal income tax purposes of $30,471,000 as of December 31, 2016. Included in these numbers are loss carry-forwards that were obtained through the acquisition of BioSeq, Inc. and are subject to Section 382 NOL limitations. These net operating loss carry-forwards expire at various dates from 2018 through 2037. We had net operating loss carry-forwards for state income tax purposes of approximately $21,547,000 at December 31, 2016. These net operating loss carry-forwards expire at various dates from 2030 through 2037. We have research and development tax credit carry-forwards for federal income tax purposes of approximately $1,039,000 as of December 31, 2016 and research and development tax credit carry-forwards for state income tax purposes of approximately $207,000 as of December 31, 2016. The federal credit carry-forwards expire at various dates from 2017 through 2037. The state credit carry-forwards expire at various dates from 2023 through 2032. In addition, we have federal alternative minimum tax credit carry-forwards for federal income tax purposes of approximately $217,000 as of December 31, 2016. These credits do not expire. Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31: 2016 2015 Federal tax provision rate 34 % 34 % Permanent differences 24 % (12 )% State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Net operating loss carry back 0 % 0 % Valuation allowance (58 )% (23 )% Effective income tax provision 0 % 0 %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(7) Commitments and Contingencies Operating Leases Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $4,800 per month, on a lease extension, signed on December 29, 2016, that expires December 31, 2017, for our corporate office. On November 1, 2014 we signed a lease for lab space in Medford, MA. We subsequently expanded our space in Medford. The lease expires December 30, 2017 and requires monthly payments of $5,385 subject to annual cost of living increases. Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2016: 2017 $ 122,220 Thereafter - Total minimum payments required $ 122,220 Royalty Commitments BioMolecular Assays, Inc. In 1996, we acquired our initial equity interest in BioSeq, Inc., which at the time was developing our original pressure cycling technology. BioSeq, Inc. acquired its pressure cycling technology from BioMolecular Assays, Inc. under a technology transfer and patent assignment agreement. In 1998, we purchased all of the remaining outstanding capital stock of BioSeq, Inc., and at such time, the technology transfer and patent assignment agreement was amended to require us to pay BioMolecular Assays, Inc., a 5% royalty on our sales of products or services that incorporate or utilize the original pressure cycling technology that BioSeq, Inc. acquired from BioMolecular Assays, Inc. We are also required to pay BioMolecular Assays, Inc. 5% of the proceeds from any sale, transfer or license of all or any portion of the original pressure cycling technology. These payment obligations terminated on March 7, 2016. During the years ended December 31, 2016 and 2015, we incurred approximately $6,963 and $31,301, respectively, in royalty expense associated with our obligation to BioMolecular Assays, Inc. In connection with our acquisition of BioSeq, Inc., we licensed certain limited rights to the original pressure cycling technology back to BioMolecular Assays, Inc. This license is non-exclusive and limits the use of the original pressure cycling technology by BioMolecular Assays, Inc. solely for molecular applications in scientific research and development and in scientific plant research and development. BioMolecular Assays, Inc. is required to pay us a royalty equal to 20% of any license or other fees and royalties, but not including research support and similar payments, it receives in connection with any sale, assignment, license or other transfer of any rights granted to BioMolecular Assays, Inc. under the license. BioMolecular Assays, Inc. was required to pay us these royalties until the expiration in March 2016 of the patents held by BioSeq, Inc. since 1998. We have not received any royalty payments from BioMolecular Assays, Inc. under this license. Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We recorded $20,000 and $22,000 of minimum royalty income in 2016 and 2015, respectively. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $1,400 for the use of a lab bench, shared space and other utilities, and $2,000 per day for technical support services as needed. Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, Lazarev, and Lawrence, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the control change.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	(8) Convertible Debt and Other Debt Senior Secured Convertible Debentures and Warrants We entered into Subscription Agreements (the “ Subscription Agreement Purchaser Debentures Warrants Purchase Price The Company issued a principal aggregate amount of $6,962,504 in Debentures which includes a 10% original issue discount on the Purchase Price. The Debenture does not accrue any additional interest during the first year it is outstanding but accrues interest at a rate equal to 10% per annum for the second year it is outstanding. The Debenture has a maturity date of two years from issuance. The Debenture is convertible any time after its issuance date. The Purchaser has the right to convert the Debenture into shares of the Company’s common stock at a fixed conversion price equal to $0.28 per share, subject to applicable adjustments. In the second year that the Debenture is outstanding, any interest accrued shall be payable quarterly in either cash or common stock, at the Company’s discretion. At any time after the Issuance Date, the Company has the option, subject to certain conditions, to redeem some or all of the then outstanding principal amount of the Debenture for cash in an amount equal to the sum of (i) 120% of the then outstanding principal amount of the Debenture, (ii) accrued but unpaid interest and (iii) any liquidated damages and other amounts due in respect of the Debenture. The Company issued warrants exercisable into a total of 11,302,766 shares of our common stock. The Warrants issued in this transaction are immediately exercisable at an exercise price of $0.40 per share, subject to applicable adjustments including full ratchet anti-dilution in the event that we issue any securities at a price lower than the exercise price then in effect. The Warrants have an expiration period of five years from the original issue date. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations and also include anti-dilution price protection for subsequent equity sales below the exercise price. Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTCQB (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days. In connection with the Subscription Agreement and Debenture, the Company entered into Security Agreements with the Purchasers whereby the Company agreed to grant to Purchasers an unconditional and continuing, first priority security interest in all of the assets and property of the Company to secure the prompt payment, performance and discharge in full of all of Company’s obligations under the Debentures, Warrants and the other Transaction Documents. The Company determined that the conversion feature of the Debentures met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature on each debt agreement and accounted for it as a derivative liability. The fair value of the conversion feature was accounted for as a note discount and are amortized to interest expense over the life of the loan. The fair value of the conversion feature was reflected in the conversion option liability line in the condensed consolidated balance sheets. The proceeds from these convertible debts were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in allocations to the convertible option and accounted for as a liability in the Company’s condensed consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds are offset by debt discounts, which are amortized to interest expense over the expected life of the debt. ASC 470-20 states that the proceeds from the issuance of debt with detachable stock warrants should be allocated between the debt and warrants on the basis of their relative fair market values. The debt discount will be amortized to interest expense over the two-year term of these loans. We amortized $3,740,746 of the debt discount to interest expense in 2016. The warrants issued in connection with the convertible debentures are classified as warrant derivative liabilities because the warrants are entitled to certain rights in subsequent financings and the warrants contain “down-round protection” and therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging, (“ASC 815”). Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $2,847,624 to the total warrants out of the gross proceeds of $6,329,549. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. Other convertible notes On May 13, 2016, one lender converted an outstanding note issued on April 28, 2015 and the related accrued interest totaling $117,837 to 420,849 common shares. As of December 31, 2016, the outstanding balance on the note was zero. On May 24, 2016, we sold an additional convertible note for $107,000 with warrants to purchase 50,000 shares of common stock at an exercise price of $0.55 per share. The purchaser has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $0.45 per share, subject to applicable adjustments. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $12,406 to the total warrants and the recognition of a beneficial conversion feature of $7,962, both of which were recorded as a discount to the note. We evaluated the convertible note and warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. On June 14, 2016, we sold an additional convertible note for $115,000 and issued 30,667 common shares to compensate the lender. On July 1, 2016, the note was modified to increase the principal amount to $200,000 and we received the remaining proceeds of $85,000 on the same date and issued 34,333 common shares as compensation to the lender. The lender has the right to convert the note into shares of the Company’s common stock at fixed conversion price equal to $0.45 per share, subject to applicable adjustments. We valued the total 65,000 common shares using the stock prices at the respective dates the note proceeds were received and recorded the relative fair value of the shares amounting to $26,000 as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financing. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. On July 29, 2016, we sold an additional convertible note for $100,000 and issued 32,500 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $0.45 per share, subject to applicable adjustments. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair values of the convertible note and the common shares was $87,241 and $12,759, respectively. We then computed the effective conversion price of the note, noting that the convertible debt gave rise to a beneficial conversion feature (BCF) of $12,759. The sum of the relative fair value of the common shares and the BCF of $25,518 was recorded as a debt discount to be amortized over the term of the loan. We also evaluated the convertible note for derivative liability treatment and determined that the instruments does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangements did not qualify for derivative accounting treatment. On September 15, 2016, we sold an additional convertible note for $500,000 and issued 200,000 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $0.45 per share, subject to applicable adjustments. The convertible note includes an original issue discount of $40,541 and is subject to a one-time interest of 9% or $45,000 which was recorded as a debt discount and amortized over the term of the loan. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair value of the convertible note was $434,028. The allocation of the gross proceeds to the shares of common stock was $65,972 and recorded as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. The specific terms of the convertible notes and outstanding balances as of December 31, 2016 are listed in the tables below. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $ 218,000 1 10 % 2 $ 388,532 $ 2,163,074 September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 1,022,052 October 2, 2015 24 months 150,000 150,000 15,000 1 10 % 2 26,345 140,832 October 6, 2015 24 months 30,000 30,000 3,000 1 10 % 2 5,168 26,721 October 14, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,954 49,377 November 2, 2015 24 months 250,000 250,000 25,000 1 10 % 2 43,079 222,723 November 10, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,790 46,984 November 12, 2015 24 months 215,000 215,000 21,500 1 10 % 2 38,518 212,399 November 20, 2015 24 months 200,000 200,000 20,000 1 10 % 2 37,185 200,000 December 4, 2015 24 months 170,000 170,000 17,000 1 10 % 2 37,352 170,000 December 11, 2015 24 months 360,000 360,000 36,000 1 10 % 2 75,449 360,000 December 18, 2015 24 months 55,000 55,000 5,500 1 10 % 2 11,714 55,000 December 31, 2015 24 months 100,000 100,000 10,000 1 10 % 2 20,634 100,000 January 11, 2016 24 months 100,000 100,000 10,000 1 10 % 2 24,966 80,034 January 20, 2016 24 months 50,000 50,000 5,000 1 10 % 2 9,812 40,188 January 29, 2016 24 months 300,000 300,000 30,000 1 10 % 2 60,887 239,113 February 26, 2016 24 months 200,000 200,000 20,000 1 10 % 2 43,952 156,048 March 10, 2016 24 months 125,000 125,000 12,500 1 10 % 2 18,260 106,740 March 18, 2016 24 months 360,000 360,000 36,000 1 10 % 2 94,992 265,008 March 24, 2016 24 months 106,667 106,667 10,667 1 10 % 2 15,427 91,240 March 31, 2016 24 months 167,882 167,882 16,788 1 10 % 2 2,436 165,446 April 5, 2016 24 months 10,000 10,000 1,000 1 10 % 2 - 10,000 May 24, 2016 7 months 100,000 100,000 7,000 0 % - 20,368 June 15, 2016 6 months 40,000 40,000 - 12 % - 3,680 June 17, 2016 6 months 40,000 40,000 - 12 % - 3,899 June 22, 2016 6 months 35,000 35,000 - 12 % - 3,373 July 6, 2016 6 months 85,000 85,000 - 12 % - 15,048 July 29, 2016 6 months 100,000 100,000 - 12 % - 25,518 September 15, 2016 8 months 500,000 500,000 85,541 9 % - 65,972 $ 7,229,549 $ 7,229,549 $ 725,496 $ 1,158,408 $ 6,060,837 1. The original issue discount is reflected in the first year. 2. The annual interest started accruing in the second year. As of December 31, 2016, a total of approximately $291,000 convertible debentures were purchased by related parties who were members of the Company’s Board of Directors and management and their family members. Deferred finance fees included cash commissions amounting to $621,500 and the fair value of the 2,101,786 warrants issued to the placement agent amounting to $536,908. For the year ended December 31, 2016, the Company recognized amortization expense related to the debt discounts indicated above of $3,876,622. The unamortized debt discounts as of December 31, 2016 related to the convertible debentures and other convertible notes amounted to $3,142,078. Revolving Note Payable On October 28, 2016, an accredited investor (the “ Investor Revolving Note Maturity Date In the event that a Qualified Offering occurs on or prior to the six (6) month anniversary of October 28, 2016, within seven (7) Business Days of the closing of the Qualified Offering, the Company shall pay a cash fee equal to five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering or, at the option of the Company, issue to the Holder a number of restricted shares of the Company’s common stock equal to (x) five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering divided by (y) the purchase price provided by the documents governing the Qualified Offering. A Qualified Offering In the event that a Qualified Offering occurs following the six (6) month anniversary of October 28, 2016, but prior to the Maturity Date, within seven(7) Business Days of the closing of the Qualified Offering, the Company shall pay a cash fee equal to five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering or, at the option of the Company, issue to the Holder a number of restricted shares of the Company’s common stock equal to (x) five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering divided by (y) the purchase price provided by the documents governing the Qualified Offering. Interest on the principal balance of the Revolving Note shall be paid in full on the Maturity Date, unless otherwise paid prior to the Maturity Date. Interest shall be assessed as follows: (i) a one-time interest of 10% on all principal amounts advanced prior to April 28, 2017; (ii) the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between April 28, 2017 and July 28, 2017; or (iii) both of the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between July 28, 2017 and October 28, 2017. Broker fees amounting to $116,500, the one-time interest of $125,000 and the fair value of the 3,125,000 warrants issued to the Investor amounting to $479,730 were recorded as debt discounts and amortized over the term of the revolving note. For the year ended December 31, 2016, the Company recognized amortization expense related to the debt discounts indicated above of $84,200. The unamortized debt discounts as of December 31, 2016 related to the convertible debentures amounted to $637,030. The following table provides a summary of the changes in convertible debt and revolving note payable, net of unamortized discounts, during 2016: 2016 Balance at January 1, $ 277,342 Issuance of convertible debt, face value 2,509,045 Issuance of revolving note payable, face value 1,250,000 Original issue discount (189,496 ) Debt discount from derivative liabilities (embedded conversion option and warrants) (1,153,817 ) Debt discount from beneficial conversion feature (20,721 ) Deferred financing fees (385,371 ) Debt discount related to one-time interest charge (170,000 ) Repayment of convertible debt (107,000 ) Conversion of convertible debt into common stock (100.000 ) Debt discount from shares and warrants issued with the notes (596,867 ) Accretion of interest and amortization of debt discount to interest expense 3,960,822 Balance at December 31, 5,273,937 Less: revolving note payable 612,970 Less: current portion of convertible debt 4,005,702 Convertible debt, long-term portion $ 655,265 Other Notes On January 15, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $150,000 in exchange for rights to all customer receipts until the lender was paid $187,500, which was collected at the rate of $744 per business day. The payments were secured by essentially all tangible assets of the Company. $67,925 of the proceeds were used to pay off the outstanding balance of a previous loan from this lender. The Company paid $1,875 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On January 29, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $200,000 in exchange for rights to all customer receipts until the lender was paid $278,000, which was collected at the rate of $1,985 per business day. The payments were secured by essentially all tangible assets of the Company. The Company paid $999 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On March 17, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $50,000 in exchange for rights to all customer receipts until the lender was paid $67,450, which was collected at the rate of $559 per business day. The payments were secured by essentially all tangible assets of the Company. The Company paid $999 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On May 29, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $100,000 in exchange for rights to all customer receipts until the lender was paid $132,000, which was collected at the rate of $1,098 per business day. The Company paid $3,999 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On August 28, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $300,000 in exchange for rights to all customer receipts until the lender is paid $384,000, to be collected at the rate of $2,560 per business day. The payments are not secured. On the closing date, $131,710 of the proceeds were used to pay off the outstanding balances of two existing Notes. The Company paid $6,000 in fees in connection with this loan. The loan was paid off in its entirety prior to December 31, 2016. During the year ended December 31, 2015, we signed three ninety-day notes with an investor. Under the terms of the notes, the Company received a total of $600,000. The investor converted these loans, plus $60,000 in accrued interest into the Company’s $5 million PIPE offering on July 21, 2015. There was no gain or loss on the conversion. During the year ended December 31, 2015, the Company made payments of $587,949 in total on the non-convertible debt from non-related parties. On January 6, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received $250,000 in exchange for rights to all customer receipts until the lender is paid $322,500, which is collected at the rate of $1,280 per business day. The payments were secured by second position rights to all customer receipts until the loan has been paid in full. $138,840 of the proceeds were used to pay off the outstanding balance of a previous loan from another lender. The Company recognized a gain on the settlement of the previous loan of $5,044 which was credited to interest expense. The Company paid $2,500 in fees in connection with this loan. We received an additional $93,161 in June 2016 under the existing Merchant Agreement. The note was still outstanding as of December 31, 2016 with a balance of $157,287. On January 20, 2016 we borrowed $50,000 from an individual with no interest or fees. We paid back the loan in March 2016. On February 8, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received $100,000 in exchange for third position rights to all customer receipts until the lender is paid $129,900, which is collected at the rate of $927 per business day. The Company paid $2,000 in fees in connection with this loan. We received an additional $125,000 in June 2016 under the existing Merchant Agreement of which $48,420 was used to pay off the prior loan. The lender provided an additional $70,000 on August 16, 2016. We repaid a portion of the $70,000 with $32,430 remaining as outstanding as of December 31, 2016. On May 9, 2016 we signed a promissory note with a lender. Under the agreement we received $200,000 net of a $6,000 original issue discount and we repaid $206,000 on August 25, 2016. In connection with this promissory note, we issued warrants exercisable into 100,000 shares of our common stock. The warrants issued in this transaction are immediately exercisable at an exercise price of $0.55 per share. The warrants have an expiration period of three years from the original issue date. The warrants are subject to adjustment for stock splits, stock dividends or recapitalizations. The warrants were recorded as a component of our Stockholders’ Equity. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $27,349 to the total warrants and recorded as a discount to the note to be amortized over the term of the loan. We evaluated the warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that these instruments did not qualify for derivative accounting treatment. In August 2016, the lender extended the maturity date of the note from August 11, 2016 to August 25, 2016. Consequently, a penalty interest of $41,200 was added to the principal amount and settled through the issuance of 100,049 common shares. As of December 31, 2016, the outstanding balance on this note was zero. On August 26, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received $122,465 net proceeds in exchange for rights to all customer receipts which is collected at the rate of $1,386 per business day. The note was still outstanding as of December 31, 2016 with a balance of $48,440. Related Party Notes During the year ended December 31, 2016, the Company received advances from certain officers of the Company amounting to $20,000. These advances were non-interest bearing and payable on demand. As of December 31, 2016 there are no outstanding notes to related parties.

Stockholders' (Deficit)

Stockholders' (Deficit)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' (Deficit)	(9) Stockholders’ (Deficit) Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock: 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock (“ Junior A 2) 313,960 shares have been designated as Series A Convertible Preferred Stock (“ Series A 3) 279,256 shares have been designated as Series B Convertible Preferred Stock (“ Series B 4) 88,098 shares have been designated as Series C Convertible Preferred Stock (“ Series C 5) 850 shares have been designated as Series D Convertible Preferred Stock (“ Series D 6) 500 shares have been designated as Series E Convertible Preferred Stock (“Series E”) 7) 240,000 shares have been designated as Series G Convertible Preferred Stock (“ Series G 8) 10,000 shares have been designated as Series H Convertible Preferred Stock (“ Series H 9) 21 shares have been designated as Series H2 Convertible Preferred Stock (“ Series H2 10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“ Series J 11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“ Series K As of December 31, 2016 and 2015, there were no shares of Junior A, and Series A, B, C, E, and H1 issued and outstanding. Series D Convertible Preferred Stock On November 11, 2011, we completed a registered direct offering, pursuant to which we sold an aggregate of 843 units for a purchase price of $1,000 per unit, resulting in gross proceeds to us of $843,000 (the “ Series D Placement Series D Unit Series D Convertible Preferred Stock Series D Warrant The proceeds from the sale of each Series D Unit were allocated between the Series D Convertible Preferred Stock and the Series D Warrants based on the residual method. The estimated fair value of the Series D Warrants was determined using a binomial formula, resulting in an allocation of the gross proceeds of $283,725 to the total warrants issued. The allocation of the gross proceeds to the Series D Convertible Preferred Stock was $559,275. In accordance with the provisions of ASC 470-20, an additional adjustment between Additional Paid in Capital and Accumulated Deficit of $530,140 was recorded to reflect an implicit non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $530,140 represents the value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series D Convertible Preferred Stock. The value adjustment was calculated by subtracting the fair market value of the underlying common stock on November 10, 2011 issuable upon conversion of the Series D Convertible Preferred Stock from the fair market value of the Series D Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series D Convertible Preferred Stock and warrants. The warrants are recorded as a liability. See “Warrant Derivative Liability” below. The Series D Convertible Preferred Stock will rank senior to the Company’s common stock and Series C Convertible Preferred Stock with respect to payments made upon liquidation, winding up or dissolution. Upon any liquidation, dissolution or winding up of the Company, after payment of the Company’s debts and liabilities, and before any payment is made to the holders of any junior securities, the holders of Series D Convertible Preferred Stock will first be entitled to be paid $1,000 per share subject to adjustment for accrued but unpaid dividends. We may not pay any dividends on shares of common stock unless we also pay dividends on the Series D Convertible Preferred Stock in the same form and amount, on an as-if-converted basis, as dividends actually paid on shares of our common stock. Except for such dividends, no other dividends may be paid on the Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock is convertible into 1,538.46 shares of common stock (based upon an initial conversion price of $0.65 per share) at any time at the option of the holder, subject to adjustment for stock splits, stock dividends, combinations, and similar recapitalization transactions (the “ Series D Conversion Ratio In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock, then following such event, the holders of the Series D Convertible Preferred Stock will be entitled to receive upon conversion of the Series D Convertible Preferred Stock the same kind and amount of securities, cash or property which the holders of the Series D Convertible Preferred Stock would have received had they converted the Series D Convertible Preferred Stock immediately prior to such fundamental transaction. The holders of Series D Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except that the holders of Series D Convertible Preferred Stock may vote separately as a class on any matters that would (i) amend, our Restated Articles of Organization, as amended, in a manner that adversely affects the rights of the Series D Convertible Preferred Stock, (ii) alter or change adversely the powers, preferences or rights of the Series D Convertible Preferred Stock or alter or amend the certificate of designation, (iii) authorize or create any class of shares ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series D Convertible Preferred Stock, or (iv) increase the number of authorized shares of Series D Convertible Preferred Stock. If, within 12 months of the initial issuance of the Series D Convertible Preferred Stock, we issue any common stock, common stock equivalents, indebtedness or any combination thereof (a “ Subsequent Financing Series D Warrants The Series D Warrants originally had an exercise price equal to $0.81 per share of common stock. In April 2012, the number of Series D Warrants increased by 530,406 to a total of 1,047,875 and each Series D Warrant had an exercise price reset to $0.40 per share of common stock. In December of 2013 the number of Series D Warrants increased by 628,733 to a total of 1,676,608 and each Series D Warrant had an exercise price reset to $0.25 per share of common stock. The Series D Warrants will be exercisable beginning on the six-month anniversary of the date of issuance and expire five years from the initial exercise date. The Series D Warrants permit the holder to conduct a “cashless exercise” at any time a registration statement registering, or the prospectus contained therein, is not available for the issuance of the shares of common stock issuable upon exercise of the Series D Warrant, and under certain circumstances at the expiration of the Series D Warrants. The exercise price and/or number of shares of common stock issuable upon exercise of the Series D Warrants are subject to adjustment for certain stock dividends, stock splits or similar capital reorganizations, as set forth in the Warrants. The exercise price is also subject to adjustment in the event that we issue any shares of common stock or common stock equivalents at a per share price that is lower than the exercise price for the Series D Warrants then in effect. Upon any such issuance, subject to certain exceptions, the exercise price will be reduced to the per share price at which such shares of common stock or common stock equivalents are issued and number of Series D Warrant shares issuable thereunder shall be increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, shall be equal to the aggregate exercise price prior to such adjustment. Unless waived under certain circumstance by the holder of a Series D Warrant, such holder may not exercise the Series D Warrant if upon such exercise the holder’s beneficial ownership of the Company’s common stock would exceed certain thresholds. In the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock, then following such event, the holders of the Series D Warrants will be entitled to receive upon exercise of the Series D Warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the Series D Warrants immediately prior to such fundamental transaction. Series G Convertible Preferred Stock On July 6 and November 15, 2012, we completed a private placement, pursuant to which we sold an aggregate of 145,320 units for a purchase price of $5.00 per unit (the “Series G Purchase Price”), resulting in gross proceeds to us of $726,600 (the “ Series G Private Placement Series G Unit Series G Warrant Each share of Series G Preferred Stock will receive a cumulative dividend at the annual rate of (i) four percent (4%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of less than $100,000, (ii) six percent (6%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $100,000 but less than $250,000, and (iii) twelve percent (12%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $250,000. Dividends accruing on the Series G Preferred Stock shall accrue from day to day until, and shall be paid within fifteen (15) days of, the first anniversary of, the original issue date of the Series G Preferred Stock; provided, however, if any shares of the Company’s Series E Preferred Stock are outstanding at such time, payment of the accrued dividends on the Series G Preferred Stock shall be deferred until no such shares of Series E Convertible Preferred Stock remain outstanding. The Company may pay accrued dividends on the Series G Preferred Stock in cash or in shares of its common stock equal to the volume weighted average price of the common stock as reported by the OTCQB for the ten (10) trading days immediately preceding the Series G’s first anniversary. At the election of the Company and upon required advanced notice, each share of Series G Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) if, after 6 months from the original issuance date of the Series G Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price equal to at least $0.75, for 7 out of 10 consecutive trading days with average daily trading volume of at least 10,000 shares, (ii) on or after the first anniversary of the original issuance date of the Series G Preferred Stock or (iii) upon completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.75, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series G Preferred Stock, such holder’s Series G Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The holders of Series G Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series G Warrants The Series G Warrants issued in the Series G Private Placement had an exercise price equal to $0.50 per share and expired on July 6, 2015. Series H Convertible Preferred Stock On December 28, 2012 the Company amended the Articles of Incorporation to authorize 10,000 shares of Series H Convertible Preferred Stock. On January 4, 2013, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 1,000,000 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 10,000 shares of a newly created series of preferred stock, designated Series H Convertible Preferred Stock, par value $0.01 per share (the “ Series H Preferred Stock Series H2 Convertible Preferred Stock On December 23, 2014 the Company amended the Articles of Incorporation to authorize 21 shares of Series H2 Convertible Preferred Stock. On December 23, 2014, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 2,100,000 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 21 shares of a newly created series of preferred stock, designated Series H2 Convertible Preferred Stock, par value $0.01 per share (the “ Series H2 Preferred Stock Series J Convertible Preferred Stock On February 6, March 28 and May 20, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 5,087.5 units for a purchase price of $400.00 per unit (the “Purchase Price”), or an aggregate Purchase Price of $2,034,700. Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series J Convertible Preferred Stock, par value $0.01 per share (the “Series J Convertible Preferred Stock”), convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 1,000 shares of common stock at an exercise price equal to $0.40 per share. The warrants expire three years from the issuance date. From the date of issuance of any shares of Series J Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series J Convertible Preferred Stock, dividends will accrue on each share of Series J Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series J Convertible Preferred Stock with an aggregate Purchase Price of less than $250,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series J Convertible Preferred Stock with an aggregate purchase price of at least $250,000. Dividends accruing on the Series J Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series J Convertible Stock, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion of the Series J Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series J Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series J Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series J Convertible Preferred Stock. The Company may pay accrued dividends on the Series J Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula. Each share of Series J Convertible Preferred Stock is convertible into 1,000 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series J Convertible Preferred Stock, such holder’s shares of Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. At the election of the Company and upon required advance notice, each share of Series J Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series J Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $0.80 for 7 out of 10 consecutive trading days with average daily trading volume of at least 50,000 shares, (ii) on the first anniversary of the original issuance date of the Series J Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.80, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series J Convertible Preferred Stock, such holder’s Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The holders of Series J Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series J Warrants The Series J Warrants issued in the Series J Private Placement had an exercise price equal to $0.40 per share and expired on February 6, March 28 and May 20, 2016. Registration Rights Agreement In connection with the Private Placement, the Company has agreed that, if, at any time after February 1, 2014, the Company files a Registration Statement relating to an offering of equity securities of the Company (the “Registration Statement”), subject to certain exceptions, including a Registration Statement relating solely to an offering or sale of securities having an aggregate public offering price of less than $5,000,000, the Company shall include in the Registration Statement the resale of the shares of common stock underlying the Warrants. Shares of common stock issued upon conversion of Series J Convertible Preferred Stock or in payment of the dividend on the Series J Convertible Preferred Stock will not be registered and will not be subject to registration rights. This right is subject to customary conditions and procedures. Series K Convertible Preferred Stock On December 12, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 4,000 units for a purchase price of $250.00 per unit (the “Purchase Price”), for an aggregate Purchase Price of $1,000,000. Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series K Convertible Preferred Stock, par value $0.01 per share (the “Series K Convertible Preferred Stock”), convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share. The warrants expire three years from the issuance date. Of the $1,000,000 invested in the Private Placement, $572,044 was received in cash and $427,956 was from the conversion of outstanding indebtedness and interest. The Company incurred $43,334 of fees in conjunction with this private placement. The purchasers in the initial tranche of the private placement consisted of certain existing and new investors in the Company as well as all of the members of the Company’s Board of Directors. From the date of issuance of any shares of Series K Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series K Convertible Preferred Stock, dividends will accrue on each share of Series K Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series K Convertible Preferred Stock with an aggregate Purchase Price of less than $100,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series K Convertible Preferred Stock with an aggregate purchase price of at least $100,000. Dividends accruing on the Series K Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series K Convertible Stock, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion of the Series K Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series K Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series K Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series K Convertible Preferred Stock. The Company may pay accrued dividends on the Series K Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula. Each share of Series K Convertible Preferred Stock is convertible into 1,000 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series K Convertible Preferred Stock, such holder’s shares of Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. At the election of the Company and upon required advance notice, each share of Series K Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series K Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $0.80 for 7 out of 10 consecutive trading days with average daily trading volume of at least 50,000 shares, (ii) on the first anniversary of the original issuance date of the Series K Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.80, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series K Convertible Preferred Stock, such holder’s Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The proceeds from the sale of each Series K Unit were allocated between the Series K Convertible Preferred Stock and the Series K Warrants based on the relative fair value method. The estimated fair value of the Series K Warrants was determined using a Black-Scholes formula, resulting in an allocation of the gross proceeds of $271,422 to the total warrants issued. The allocation of the gross proceeds to the Series K Convertible Preferred Stock was $685,245, net of $43,334 in fees. In accordance with the provisions of ASC 470-20, an additional adjustment in the aggregate between Additional Paid in Capital and Accumulated Deficit of $1,495,415 was recorded for all tranches of Series K to reflect an implicit, deemed non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $1,495,415 represents the aggregate value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series K Convertible Preferred Stock. The value adjustment was calculated by subtracting the fair market value of the underlying common stock on the closing dates issuable upon conversion of the Series K Convertible Preferred Stock from the fair market value of the Series K Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series K Convertible Preferred Stock and warrants. On January 29, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 4,875 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $1,218,750. This was the second tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the second tranche of the Private Placement consisted of certain existing and new investors in the Company, as well as all of the members of the Company’s board of directors. Each unit purchased in the second tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share, convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share, with a term expiring on January 29, 2017. On February 28, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,854 units for a purchase price of $340.00 per unit or an aggregate Purchase Price of $630,360. This was the third tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the third tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the third tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.425 per share, with a term expiring on February 28, 2017. On June 30, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 734 units for a purchase price of $300.00 per unit or an aggregate Purchase Price of $220,000. This was the fourth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the fourth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.375 per share, with a term expiring on June 30, 2017. On November 12, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,052 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $263,000. This was the fifth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the fifth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share, with a term expiring on November 12, 2017. The Private Placement was originally expected to raise $1.5 million and close on or before January 31, 2014. On January 29, 2014, the Company’s Board of Directors voted to increase the subscription amount of the Private Placement by $718,750. The Board of Directors also voted to extend the Private Placement until February 28, 2014. On February 28, 2014 the Company’s Board of Directors voted to increase the subscription amount once again to a total of $3.5 million and extended the closing to April 4, 2014. On April 13, 2014 the Company’s Board of Directors voted to increase the subscription amount by $1 million, to a total of $4.5 million, and extended the closing to May 31, 2014. On July 7, 2014 the Company’s Board of Directors voted to extend the closing to August 15, 2014. Together with the initial tranche of $1,000,000 that closed on December 12, 2013, the second tranche of $1,218,750 that closed January 29, 2014, the third tranche of $630,360 that closed February 28, 2014, the fourth tranche of $220,000 that closed June 30, 2014, and the fifth tranche of $263,000 that closed November 12, 2014,the total consideration received by the Company in the Private Placement is $3,332,110, which is comprised of $2,511,404 in cash and $820,706 from the conversion of outstanding indebtedness and Board of Director fees. The placement was closed after the November 12, 2014 round. On September 22, 2014 the Company issued 64,000 shares of common stock for the conversion of 64 shares of Series K Preferred Convertible Stock. In connection with the Series K Warrants, we calculated the fair value of the warrants received as described above using the Black- Scholes formula with the below assumptions: Assumptions Series K Warrants December 12, 2013 Series K Warrants January 29, 2014 Series K Warrants February 28, 2014 Series K Warrants June 30, 2014 Series K Warrants November 12, 2014 Contractual life (in months) 36 36 36 36 36 Expected volatility 136.1 152.4 152.7 153.9 153.9 Risk-free interest rate 0.39 % 0.39 % 0.39 % 0.90 % 0.90 % Exercise price $ 0.3125 $ 0.3125 $ 0.425 $ 0.375 $ 0.3125 Fair value per warrant $ 0.20 $ 0.30 $ 0.37 $ 0.29 $ 0.23 The holders of Series K Convertible Preferred Stock are not entitle

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	(10) Subsequent Events On March 21, 2017, we received an eight-month, non-convertible loan of $170,000 from an accredited investor. The loan earns an annual interest rate of 10% and includes a 10% original issue discount. We also agreed to issue the investor 170,000 shares of restricted common stock. On March 16, 2017, we awarded 660,000 incentive stock options to certain employees and 1,855,000 non-qualified stock options to officers, consultants and directors of the Company. Terms of the stock options include the following significant items: (i) $0.28 exercise price, (ii) 10-year life, (iii) 36 month vesting equally per month for employees and 12 month vesting equally per month for directors, (iv) options vest immediately upon change in-control. On March 14, 2017, we received an eight-month, non-convertible loan of $250,000 from a privately-held investment firm. The loan earns an annual interest rate of 10% and includes a 10% original issue discount. We also agreed to issue the investor 250,000 shares of restricted common stock. On March 2, 2017, we signed a Merchant Agreement with a lender. Under the agreement we received a loan of $75,000. The Company paid no fees in connection with this loan. On February 15, 2017, we received a six-month, non-convertible loan of $110,000 from each of two accredited investors. We agreed to issue the investors 170,000 shares of restricted common stock. The loans earn no interest but carry a 10% original issue fee. On February 6, 2017, we signed a Merchant Agreement with a lender. Under the agreement we received a loan of $125,000. The Company paid $1,250 in fees in connection with this loan. Under the agreement, $16,180 was used to pay off the prior loan. We received $250,000 in January 2017 and $500,000 in February 2017 pursuant to the October Revolving Note and we issued to the Investor additional warrants to purchase 1,875,000 shares of our common stock. The terms of the Warrants are identical except for the exercise date, issue date, and termination date. Interest on the principal balance of the Revolving Note shall be paid in full on the Maturity Date, unless otherwise paid prior to the Maturity Date. On January 17, 2017, we signed a one-year agreement with an investor relations firm. We have the right to terminate the agreement within 10 days of the end of each three-month period. We are committed to pay the IR firm $25,000 for each three-month term, in three equal monthly allotments, should we choose to keep them under contract. We also have awarded the IR firm warrants to purchase the Company’s restricted common stock at an exercise price of $0.40/share. The number of warrants and exercise price that we are committed to pay the IR firm for each three-month period, should we choose to keep them under contract, is as follows: Months 1-3: 100,000 warrants at $0.40. Months 4-6: 125,000 warrants at $0.60. Months 7-9: 125,000 warrants at $0.80. Months 10-12: 150,000 warrants at $1.00. In January 2017, we executed an amendment to the July 1, 2016 convertible note that was due on January 6, 2017. We received an extension of up to three months on the note’s due date. In exchange for the extension, we agreed to issue 50,000 shares of restricted common stock and pay the investor $10,000 for each 30-day extension. We made a payment of $34,000 in January 2017 for the first one-month extension and interest on the note from the initial close date through February 6, 2017. On February 28, 2017, the note was paid in full.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Revenue Recognition	iii. Revenue Recognition Revenue is recognized when realized or when realizable and earned when all the following criteria have been met: persuasive evidence of an arrangement exists; goods were shipped, delivery of service has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. Our current instruments, the Barocycler NEP3229 and NEP2320, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon shipment of the unit, or in the case where the customer requests installation and training, the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue. The Company applies ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. The Company currently records revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when qualifying expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and the Company’s service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying deliverables. Revenue from service contracts is recorded ratably over the length of the contract. Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”)
Cash and Cash Equivalents	iv. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents.
Research and Development	v. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
Inventories	vi. Inventories Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: 2016 2015 Raw materials $ 326,228 $ 310,367 Finished goods 599,056 778,004 Inventory reserve (20,000 ) (50,000 ) Total $ 905,284 $ 1,038,371
Property and Equipment	vii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
Intangible Assets	viii. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over sixteen years. We perform an annual review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2016 and 2015, the outstanding balance for intangible assets is zero.
Long-Lived Assets	ix. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment
Concentrations	x. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2016 and 2015, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2016 2015 Top Five Customers 29 % 38 % Federal Agencies 3 % 23 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2016 2015 Top Five Customers 82 % 93 % Federal Agencies 1 % 1 % Investment in Available-For-Sale Equity Securities As of December 31, 2016, we held 601,500 shares of common stock of Everest, a Polish publicly traded company listed on the Warsaw Stock Exchange. We exchanged 1,000,000 shares of our common stock for the 601,500 shares from Everest. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”
Computation of Loss per Share	xi. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: 2016 2015 Numerator: Net loss $ (2,706,984 ) $ (7,415,298 ) Preferred dividends accrued - (23,194 ) Net loss applicable to common shareholders $ (2,706,984 ) $ (7,438,492 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 27,339,362 20,726,205 Loss per common share - basic and diluted $ (0.10 ) $ (0.36 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2016 2015 Stock options 5,269,250 5,571,250 Convertible debt 26,733,955 19,689,286 Common stock warrants 26,459,695 29,227,664 Convertible preferred stock: Series D Convertible Preferred 750,000 750,000 Series G Convertible Preferred 865,700 865,700 Series H Convertible Preferred 1,000,000 1,000,000 Series H2 Convertible Preferred 2,100,000 2,100,000 Series J Convertible Preferred 3,521,000 3,546,000 Series K Convertible Preferred 6,816,000 11,416,000 73,515,600 74,165,900
Accounting for Income Taxes	xii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2016 and 2015, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2016 and 2015.
Accounting for Stock-Based Compensation	xiii. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee awards are accounted for under ASC 718 where the awards are valued at grant date. Awards given to nonemployees are accounted for under ASC 505 where the awards are valued at earlier of commitment date or completion of services. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2015: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs) 6.0 (yrs) Expected volatility 116.32%-141.15 % 116.32%-141.15 % Risk-free interest rate 0.65%-2.54 % 0.65%-2.54 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 % We recognized stock-based compensation expense of $379,964 and $208,989 for the years ended December 31, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: 2016 2015 Research and development $ 65,500 $ 50,617 Selling and marketing 42,315 32,704 General and administrative 272,149 125,668 Total stock-based compensation expense $ 379,964 $ 208,989 During the years ended December 31, 2016 and 2015, the total fair value of stock options awarded was $0 and $598,582, respectively. As of December 31, 2016, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $369,224. The non-cash, stock based compensation expense associated with the vesting of these options will be $212,957 in 2017 and $156,267 in 2018.
Advertising	xiv. Advertising Advertising costs are expensed as incurred. We incurred $19,125 in 2016 and $12,291 in 2015 for advertising.
Fair Value of Financial Instruments	xv. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value.
Fair Value Measurements	xvi. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1 and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy. The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2016 and December 31, 2015. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2016 using: December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 25,865 25,865 - - Total Financial Assets $ 25,865 $ 25,865 $ - $ - December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 23,313 - - $ 23,313 Warrants Issued with Convertible Debt 1,661,795 - - 1,661,795 Conversion Option Derivative Liabilities 951,059 - - 951,059 Total Derivatives $ 2,636,167 $ - $ - $ 2,636,167 Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 294,522 294,522 - - Total Financial Assets $ 294,522 $ 294,522 $ - $ - December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 - - $ 173,526 Warrants Issued with Convertible Debt 3,122,450 - - 3,122,450 Conversion Option Derivative Liabilities 3,940,791 - - 3,940,791 Total Derivatives $ 7,236,767 $ - $ - $ 7,236,767 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2016 Issuance fair value Change in fair value December 31, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ - $ (150,213 ) $ 23,313 Warrants Issued with Convertible Debt 3,122,450 1,094,432 (2,555,087 ) 1,661,795 Conversion Option Derivative Liabilities 3,940,791 1,547,127 (4,536,859 ) 951,059 Total Derivatives $ 7,236,767 $ 2,641,559 $ (7,242,159 ) $ 2,636,167 January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ 13,651 $ - $ 173,526 Warrants Issued with Convertible Debt - 2,320,021 802,429 - 3,122,450 Conversion Option Derivative Liabilities 590,341 5,305,185 600,445 (2,555,180 ) 3,940,791 Total Derivatives $ 750,216 $ 7,625,206 $ 1,416,525 $ (2,555,180 ) $ 7,236,767 The issuance fair values for 2016 and 2015 include the “day 1” derivative losses on the conversion option derivative liabilities of $1,337,510 and $805,476, respectively, which are included in “change in fair value of derivative liabilities” in the consolidated statements of operations. The fair value of the derivative liabilities was determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2015 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 11.0 5.0 Expected volatility 104.5 % 104.9 % 83.5 % Risk-free interest rate 0.875 % 0.65 % 0.62 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.16 $ 0.02 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2015 and 2016 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 55.0-60.0 43.0-51.0 Expected volatility 118.3-120.1 % 136.3-141.6 % 110.0-116.0 % Risk-free interest rate 1.48-1.69 % 1.29-1.76 % 1.93 % Exercise price $ 0.40 $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$0.21 $ 0.30 $ 0.12-0.14 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2015 Conversion options revalued at December 31, 2016 Expected life (in months) 6.0-24.0 0-18.0 18-24 6.0-15.0 Expected volatility 104.2-153.8 % 86.9%-142.2 % 112.2-114.7 % 84.4-94.8 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 1.06 % 0.62-0.85 % Exercise price $ 0.10-$0.35 $ 0.10-$0.25 $ 0.28 $ 0.28 Fair value per conversion option $ 0.09-$0.28 $ 0.07-$0.26 $ 0.14-$0.33 $ 0.03-$0.06
Recently Issued Accounting Standards	xvii. Recently Issued Accounting Standards In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company early-adopted ASU 2015-03 as of the end of its Fiscal 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 resulted in the reclassification of approximately $888,000 unamortized debt issuance costs related to the Company’s Senior Notes (see Note 8) from other non-current assets to long-term debt within its consolidated balance sheets as of December 31, 2015. Other than this reclassification, the adoption of ASU 2015-03 and other new pronouncements that have been issued did not have an impact on the Company’s consolidated financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Inventories	The composition of inventory as of December 31, is as follows: 2016 2015 Raw materials $ 326,228 $ 310,367 Finished goods 599,056 778,004 Inventory reserve (20,000 ) (50,000 ) Total $ 905,284 $ 1,038,371
Summary of Customer Concentration Risk Percentage	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2016 2015 Top Five Customers 29 % 38 % Federal Agencies 3 % 23 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2016 2015 Top Five Customers 82 % 93 % Federal Agencies 1 % 1 %
Summary of Computation of Loss per Share	The following table illustrates our computation of loss per share for the years ended December 31: 2016 2015 Numerator: Net loss $ (2,706,984 ) $ (7,415,298 ) Preferred dividends accrued - (23,194 ) Net loss applicable to common shareholders $ (2,706,984 ) $ (7,438,492 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 27,339,362 20,726,205 Loss per common share - basic and diluted $ (0.10 ) $ (0.36 )
Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2016 2015 Stock options 5,269,250 5,571,250 Convertible debt 26,733,955 19,689,286 Common stock warrants 26,459,695 29,227,664 Convertible preferred stock: Series D Convertible Preferred 750,000 750,000 Series G Convertible Preferred 865,700 865,700 Series H Convertible Preferred 1,000,000 1,000,000 Series H2 Convertible Preferred 2,100,000 2,100,000 Series J Convertible Preferred 3,521,000 3,546,000 Series K Convertible Preferred 6,816,000 11,416,000 73,515,600 74,165,900
Summary of Assumptions for Grants of Stock Options	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2015: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs) 6.0 (yrs) Expected volatility 116.32%-141.15 % 116.32%-141.15 % Risk-free interest rate 0.65%-2.54 % 0.65%-2.54 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 %
Summary of Stock Based Compensation Expense	The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: 2016 2015 Research and development $ 65,500 $ 50,617 Selling and marketing 42,315 32,704 General and administrative 272,149 125,668 Total stock-based compensation expense $ 379,964 $ 208,989
Schedule of Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2016 and December 31, 2015. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2016 using: December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 25,865 25,865 - - Total Financial Assets $ 25,865 $ 25,865 $ - $ - December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 23,313 - - $ 23,313 Warrants Issued with Convertible Debt 1,661,795 - - 1,661,795 Conversion Option Derivative Liabilities 951,059 - - 951,059 Total Derivatives $ 2,636,167 $ - $ - $ 2,636,167 Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 294,522 294,522 - - Total Financial Assets $ 294,522 $ 294,522 $ - $ - December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 - - $ 173,526 Warrants Issued with Convertible Debt 3,122,450 - - 3,122,450 Conversion Option Derivative Liabilities 3,940,791 - - 3,940,791 Total Derivatives $ 7,236,767 $ - $ - $ 7,236,767 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2016 Issuance fair value Change in fair value December 31, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ - $ (150,213 ) $ 23,313 Warrants Issued with Convertible Debt 3,122,450 1,094,432 (2,555,087 ) 1,661,795 Conversion Option Derivative Liabilities 3,940,791 1,547,127 (4,536,859 ) 951,059 Total Derivatives $ 7,236,767 $ 2,641,559 $ (7,242,159 ) $ 2,636,167 January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ 13,651 $ - $ 173,526 Warrants Issued with Convertible Debt - 2,320,021 802,429 - 3,122,450 Conversion Option Derivative Liabilities 590,341 5,305,185 600,445 (2,555,180 ) 3,940,791 Total Derivatives $ 750,216 $ 7,625,206 $ 1,416,525 $ (2,555,180 ) $ 7,236,767
Schedule of Fair Value Assumptions	The fair value of the derivative liabilities was determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2015 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 11.0 5.0 Expected volatility 104.5 % 104.9 % 83.5 % Risk-free interest rate 0.875 % 0.65 % 0.62 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.16 $ 0.02 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2015 and 2016 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 55.0-60.0 43.0-51.0 Expected volatility 118.3-120.1 % 136.3-141.6 % 110.0-116.0 % Risk-free interest rate 1.48-1.69 % 1.29-1.76 % 1.93 % Exercise price $ 0.40 $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$0.21 $ 0.30 $ 0.12-0.14 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2015 Conversion options revalued at December 31, 2016 Expected life (in months) 6.0-24.0 0-18.0 18-24 6.0-15.0 Expected volatility 104.2-153.8 % 86.9%-142.2 % 112.2-114.7 % 84.4-94.8 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 1.06 % 0.62-0.85 % Exercise price $ 0.10-$0.35 $ 0.10-$0.25 $ 0.28 $ 0.28 Fair value per conversion option $ 0.09-$0.28 $ 0.07-$0.26 $ 0.14-$0.33 $ 0.03-$0.06

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of December 31, 2016 and 2015 consisted of the following components: December 31, 2016 2015 Laboratory and manufacturing equipment $ 226,326 $ 226,081 Office equipment 165,832 158,872 Leasehold improvements 8,117 8,117 PCT collaboration, demonstration and leased systems 461,858 461,858 Total property and equipment 862,133 854,928 Less accumulated depreciation (852,720 ) (834,779 ) Net book value $ 9,413 $ 20,149

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Deferred Tax Liabilities	Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2016 and 2015 are as follows: 2016 2015 Current deferred taxes Inventories $ 7,856 $ 19,640 Accounts receivable allowance 17,253 - Other accruals 33,399 23,714 Less: valuation allowance (58,508 ) (43,354 ) Total current deferred tax assets $ - $ - Long term deferred taxes: Accelerated tax depreciation $ 14,582 $ 14,134 Non-cash, stock-based compensation, nonqualified 711,676 562,426 Impairment loss on investment 146,782 - Goodwill and intangibles - - Operating loss carry forwards and tax credits 13,561,012 12,028,900 Less: valuation allowance (14,434,052 ) (12,605,460 ) Total long term deferred tax assets (liabilities), net - - Total net deferred tax liabilities $ - $ -
Schedule of Effective Income Tax (Benefit) Provision Rate	Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31: 2016 2015 Federal tax provision rate 34 % 34 % Permanent differences 24 % (12 )% State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Net operating loss carry back 0 % 0 % Valuation allowance (58 )% (23 )% Effective income tax provision 0 % 0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2016: 2017 $ 122,220 Thereafter - Total minimum payments required $ 122,220

Convertible Debt and Other De23

Convertible Debt and Other Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible notes and outstanding balances as of December 31, 2016 are listed in the tables below. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $ 218,000 1 10 % 2 $ 388,532 $ 2,163,074 September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 1,022,052 October 2, 2015 24 months 150,000 150,000 15,000 1 10 % 2 26,345 140,832 October 6, 2015 24 months 30,000 30,000 3,000 1 10 % 2 5,168 26,721 October 14, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,954 49,377 November 2, 2015 24 months 250,000 250,000 25,000 1 10 % 2 43,079 222,723 November 10, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,790 46,984 November 12, 2015 24 months 215,000 215,000 21,500 1 10 % 2 38,518 212,399 November 20, 2015 24 months 200,000 200,000 20,000 1 10 % 2 37,185 200,000 December 4, 2015 24 months 170,000 170,000 17,000 1 10 % 2 37,352 170,000 December 11, 2015 24 months 360,000 360,000 36,000 1 10 % 2 75,449 360,000 December 18, 2015 24 months 55,000 55,000 5,500 1 10 % 2 11,714 55,000 December 31, 2015 24 months 100,000 100,000 10,000 1 10 % 2 20,634 100,000 January 11, 2016 24 months 100,000 100,000 10,000 1 10 % 2 24,966 80,034 January 20, 2016 24 months 50,000 50,000 5,000 1 10 % 2 9,812 40,188 January 29, 2016 24 months 300,000 300,000 30,000 1 10 % 2 60,887 239,113 February 26, 2016 24 months 200,000 200,000 20,000 1 10 % 2 43,952 156,048 March 10, 2016 24 months 125,000 125,000 12,500 1 10 % 2 18,260 106,740 March 18, 2016 24 months 360,000 360,000 36,000 1 10 % 2 94,992 265,008 March 24, 2016 24 months 106,667 106,667 10,667 1 10 % 2 15,427 91,240 March 31, 2016 24 months 167,882 167,882 16,788 1 10 % 2 2,436 165,446 April 5, 2016 24 months 10,000 10,000 1,000 1 10 % 2 - 10,000 May 24, 2016 7 months 100,000 100,000 7,000 0 % - 20,368 June 15, 2016 6 months 40,000 40,000 - 12 % - 3,680 June 17, 2016 6 months 40,000 40,000 - 12 % - 3,899 June 22, 2016 6 months 35,000 35,000 - 12 % - 3,373 July 6, 2016 6 months 85,000 85,000 - 12 % - 15,048 July 29, 2016 6 months 100,000 100,000 - 12 % - 25,518 September 15, 2016 8 months 500,000 500,000 85,541 9 % - 65,972 $ 7,229,549 $ 7,229,549 $ 725,496 $ 1,158,408 $ 6,060,837 1. The original issue discount is reflected in the first year. 2. The annual interest started accruing in the second year.
Summary of Changes in Convertible Debt, Net of Unamortized Discounts	The following table provides a summary of the changes in convertible debt and revolving note payable, net of unamortized discounts, during 2016: 2016 Balance at January 1, $ 277,342 Issuance of convertible debt, face value 2,509,045 Issuance of revolving note payable, face value 1,250,000 Original issue discount (189,496 ) Debt discount from derivative liabilities (embedded conversion option and warrants) (1,153,817 ) Debt discount from beneficial conversion feature (20,721 ) Deferred financing fees (385,371 ) Debt discount related to one-time interest charge (170,000 ) Repayment of convertible debt (107,000 ) Conversion of convertible debt into common stock (100.000 ) Debt discount from shares and warrants issued with the notes (596,867 ) Accretion of interest and amortization of debt discount to interest expense 3,960,822 Balance at December 31, 5,273,937 Less: revolving note payable 612,970 Less: current portion of convertible debt 4,005,702 Convertible debt, long-term portion $ 655,265

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Schedule of Assumption Used	In connection with the Series K Warrants, we calculated the fair value of the warrants received as described above using the Black- Scholes formula with the below assumptions: Assumptions Series K Warrants December 12, 2013 Series K Warrants January 29, 2014 Series K Warrants February 28, 2014 Series K Warrants June 30, 2014 Series K Warrants November 12, 2014 Contractual life (in months) 36 36 36 36 36 Expected volatility 136.1 152.4 152.7 153.9 153.9 Risk-free interest rate 0.39 % 0.39 % 0.39 % 0.90 % 0.90 % Exercise price $ 0.3125 $ 0.3125 $ 0.425 $ 0.375 $ 0.3125 Fair value per warrant $ 0.20 $ 0.30 $ 0.37 $ 0.29 $ 0.23
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Total Shares Weighted Average price per share Shares Weighted Average price per share Shares Exercisable Balance outstanding, January 1, 2015 3,406,250 $ 0.51 19,182,201 $ 0.49 22,588,451 20,858,111 Granted 2,500,000 0.40 10,837,141 0.40 13,337,141 Exercised - - - - - Expired (205,000 ) 1.00 (791,678 ) 0.31 (996,678 ) Forfeited (130,000 ) 0.70 - - (130,000 ) Balance outstanding, December 31, 2015 5,571,250 $ 0.44 29,227,664 $ 0.44 34,798,914 31,664,469 Granted - - 8,179,552 0.42 8,179,552 Exercised - - (70,000 ) 0.31 (70,000 ) Expired (186,000 ) 1.00 (10,877,521 ) 0.55 (11,063,521 ) Forfeited (116,000 ) 0.51 - - (116,000 ) Balance outstanding, December 31, 2016 5,269,250 $ 0.42 26,459,695 $ 0.40 31,728,945 29,730,959
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $0.30 - $0.39 1,625,500 7.7 $ 0.30 1,342,762 7.7 $ 0.30 0.40 - 0.49 2,786,000 8.7 0.40 1,454,665 8.4 0.40 0.50 - 0.59 226,250 5.6 0.50 226,250 5.6 0.50 0.60 - 0.69 385,500 3.1 0.60 385,500 3.1 0.60 0.70 - 1.25 246,000 2.3 1.00 246,000 2.3 1.00 $0.30 - $1.25 5,269,250 7.6 $ 0.42 3,655,177 7.1 $ 0.43

Business Overview (Details Narr

Business Overview (Details Narrative)	12 Months Ended
	Dec. 31, 2016lb
Pounds per square inch	35,000
PBI Europe [Member]
Percentage of ownership interest	49.00%
Investment Bank [Member]
Percentage of ownership interest	51.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)
Going Concern Details Narrative
Net proceeds from additional convertible and non-convertible debt	$ 4,378,371

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Intangible assets amortization of straight line period	16 years
Intangible assets	$ 0	$ 0
Impairment loss on investment	$ 373,682
Forfeiture rate percentage	5.00%
Stock-based compensation expense	$ 379,964	208,989
Fair value of stock options awarded	0	598,582
Fair value of unvested stock options amortized	369,224
Advertising costs	19,125	12,291
Derivative liabilities	1,337,510	805,476
Accounting Standards Update 2015-03 [Member]
Reclassification of unamortized debt issuance costs		$ 888,000
2017 [Member]
Fair value of stock options awarded	212,957
2018 [Member]
Fair value of stock options awarded	$ 156,267
Everest[Member]
Sale of stock number of shares recevied	601,500
Number of common stock shares exchanged during the period	1,000,000
Everest Investments Holdings S.A. [Member]
Fair value of investment	$ 25,865
Shares closing price per share	$ 0.043
Laboratory Equipment [Member]
Property and equipment estimated useful life	3 years
Management Information Systems And Office Equipment [Member] | Minimum [Member]
Property and equipment estimated useful life	3 years
Management Information Systems And Office Equipment [Member] | Maximum [Member]
Property and equipment estimated useful life	5 years
PCT Collaboration, Demonstration and Leased Systems [Member]
Property and equipment estimated useful life	3 years

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Raw materials	$ 326,228	$ 310,367
Finished goods	599,056	778,004
Inventory Reserve	(20,000)	(50,000)
Total	$ 905,284	$ 1,038,371

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Summary of Customer Concentration Risk Percentage (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Top Five Customers [Member] | Revenue [Member]
Concentration as a percentage	29.00%	38.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Concentration as a percentage	82.00%	93.00%
Federal Agencies [Member] | Revenue [Member]
Concentration as a percentage	3.00%	23.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Concentration as a percentage	1.00%	1.00%

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Summary of Computation of Loss per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Net loss	$ (2,706,984)	$ (7,415,298)
Preferred dividends accrued		(23,194)
Net loss applicable to common shareholders	$ (2,706,984)	$ (7,438,492)
Weighted average common stock shares outstanding	27,339,362	20,726,205
Loss per common share - basic and diluted	$ (0.10)	$ (0.36)

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total potentially dilutive shares	73,515,600	74,165,900
Stock Options [Member]
Total potentially dilutive shares	5,269,250	5,571,250
Convertible Debt [Member]
Total potentially dilutive shares	26,733,955	19,689,286
Common Stock Warrants [Member]
Total potentially dilutive shares	26,459,695	29,227,664
Series D Convertible Preferred Stock [Member]
Total potentially dilutive shares	750,000	750,000
Series G Convertible Preferred Stock [Member]
Total potentially dilutive shares	865,700	865,700
Series H Convertible Preferred Stock [Member]
Total potentially dilutive shares	1,000,000	1,000,000
Series H2 Convertible Preferred Stock [Member]
Total potentially dilutive shares	2,100,000	2,100,000
Series J Convertible Preferred Stock [Member]
Total potentially dilutive shares	3,521,000	3,546,000
Series K Convertible Preferred Stock [Member]
Total potentially dilutive shares	6,816,000	11,416,000

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Summary of Assumptions for Grants of Stock Options (Details)	12 Months Ended
	Dec. 31, 2016
Forfeiture rate	5.00%
Non-Employee Board Members [Member]
Expected life	6 years
Expected volatility Minimum	116.32%
Expected volatility Maximum	141.15%
Risk-free interest rate Minimum	0.65%
Risk-free interest rate Maximum	2.54%
Forfeiture rate	5.00%
Expected dividend yield	0.00%
CEO, other Officers and Employees [Member]
Expected life	6 years
Expected volatility Minimum	116.32%
Expected volatility Maximum	141.15%
Risk-free interest rate Minimum	0.65%
Risk-free interest rate Maximum	2.54%
Forfeiture rate	5.00%
Expected dividend yield	0.00%

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Summary of Stock Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total stock-based compensation expense	$ 379,964	$ 208,989
Research and Development [Member]
Total stock-based compensation expense	65,500	50,617
Selling and Marketing [Member]
Total stock-based compensation expense	42,315	32,704
General and Administrative [Member]
Total stock-based compensation expense	$ 272,149	$ 125,668

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total Financial Assets	$ 25,865	$ 294,522
Fair value of derivative liability	2,636,167	7,236,767
Balance	7,236,767	750,216
Issuance fair value	2,641,559	7,625,206
Change in Fair Value	(7,242,159)	1,416,525
Gain on extinguishment of derivative liabilities		(2,555,180)
Balance	2,636,167	7,236,767
Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	25,865	294,522
Fair value of derivative liability
Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Fair value of derivative liability
Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets
Fair value of derivative liability	2,636,167	7,236,767
Available-For-Sale Equity Securities [Member]
Total Financial Assets	25,865	294,522
Balance	294,522
Balance	59,550	294,522
Available-For-Sale Equity Securities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	25,865	294,522
Available-For-Sale Equity Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Available-For-Sale Equity Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets
Series D Preferred Stock Purchase Warrants [Member]
Fair value of derivative liability	23,313	173,526
Balance	173,526	159,875
Issuance fair value
Change in Fair Value	(150,213)	13,651
Gain on extinguishment of derivative liabilities
Balance	23,313	173,526
Series D Preferred Stock Purchase Warrants [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	23,313	173,526
Warrants Issued with Convertible Debt [Member]
Fair value of derivative liability	1,661,795	3,122,450
Balance	3,122,450
Issuance fair value	1,094,432	2,320,021
Change in Fair Value	(2,555,087)	802,429
Gain on extinguishment of derivative liabilities
Balance	1,661,795	3,122,450
Warrants Issued with Convertible Debt [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	1,661,795	3,122,450
Conversion Option Derivative Liabilities [Member]
Fair value of derivative liability	951,059	3,940,791
Balance	3,940,791	590,341
Issuance fair value	1,547,127	5,305,185
Change in Fair Value	(4,536,859)	600,445
Gain on extinguishment of derivative liabilities		(2,555,180)
Balance	951,059	3,940,791
Conversion Option Derivative Liabilities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	$ 951,059	$ 3,940,791

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Schedule of Fair Value Assumptions (Details) - $ / shares	Nov. 10, 2011	Dec. 31, 2016	Dec. 31, 2015
Expected life (in months)	60 months
Expected volatility	104.50%
Risk-free interest rate	0.875%
Exercise price	$ 0.81
Fair value per share	$ 0.54
Warrants Revalued at December 31, 2015 [Member]
Expected life (in months)			11 months
Expected volatility			104.90%
Risk-free interest rate			0.65%
Exercise price			$ .25
Fair value per share			0.16
Warrants Revalued at December 31, 2016 [Member]
Expected life (in months)		5 months
Expected volatility		83.50%
Risk-free interest rate		0.62%
Exercise price		$ 0.25
Fair value per share		$ 0.02
Warrants Revalued at December 31, 2016 [Member] | Warrants Issued with Convertible Debt [Member]
Risk-free interest rate		1.93%
Exercise price		$ 0.40	0.40
Fair value per share			$ 0.30
Warrants Revalued at December 31, 2016 [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected life (in months)		43 months	55 years
Expected volatility		110.00%	136.30%
Risk-free interest rate			1.29%
Fair value per share		$ 0.12
Warrants Revalued at December 31, 2016 [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected life (in months)		51 months	60 years
Expected volatility		116.00%	141.60%
Risk-free interest rate			1.76%
Fair value per share		$ 0.14
Issuance Fair Value [Member] | Minimum [Member]
Expected life (in months)		6 months
Expected volatility		104.20%
Risk-free interest rate		0.05%
Exercise price		$ 0.10
Fair value per share		$ 0.09
Issuance Fair Value [Member] | Maximum [Member]
Expected life (in months)		24 months
Expected volatility		153.80%
Risk-free interest rate		0.99%
Exercise price		$ 0.35
Fair value per share		$ 0.28
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member]
Expected life (in months)		60 months
Exercise price		$ 0.40
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected volatility		118.30%
Risk-free interest rate		1.48%
Fair value per share		$ 0.19
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected volatility		120.10%
Risk-free interest rate		1.69%
Fair value per share		$ 0.21
At Settlement Fair Value [Member] | Minimum [Member]
Expected life (in months)		0 months
Expected volatility		86.90%
Risk-free interest rate		0.01%
Exercise price		$ 0.10
Fair value per share		$ 0.07
At Settlement Fair Value [Member] | Maximum [Member]
Expected life (in months)		18 months
Expected volatility		142.20%
Risk-free interest rate		0.72%
Exercise price		$ 0.25
Fair value per share		0.26
Conversion Options Revalued at December 31, 2015 [Member]
Exercise price			$ 0.28
Conversion Options Revalued at December 31, 2015 [Member] | Minimum [Member]
Expected life (in months)			18 years
Expected volatility			112.20%
Fair value per share			$ 0.33
Conversion Options Revalued at December 31, 2015 [Member] | Maximum [Member]
Expected life (in months)			24 years
Expected volatility			114.70%
Fair value per share			$ 0.14
Conversion Options Revalued at December 31, 2016 [Member]
Exercise price		$ 0.28
Conversion Options Revalued at December 31, 2016 [Member] | Minimum [Member]
Expected life (in months)		6 months
Expected volatility		84.40%
Risk-free interest rate		0.62%
Fair value per share		$ 0.03
Conversion Options Revalued at December 31, 2016 [Member] | Maximum [Member]
Expected life (in months)		15 months
Expected volatility		94.80%
Risk-free interest rate		0.85%
Fair value per share		$ 0.06

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property And Equipment Net Details Narrative
Depreciation expense	$ 17,939	$ 25,288

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property And Equipment Net - Schedule Of Property And Equipment Details
Laboratory and manufacturing equipment	$ 226,326	$ 226,081
Office equipment	165,832	158,872
Leasehold improvements	8,117	8,117
PCT collaboration, demonstration and leased systems	461,858	461,858
Total property and equipment	862,133	854,928
Less accumulated depreciation	(852,720)	(834,779)
Net book value	$ 9,413	$ 20,149

Retirement Plan (Details Narrat

Retirement Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Company-matching contributions	$ 22,627	$ 22,098

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Research and development tax credit carryforwards	$ 14,582	$ 14,134
Federal Income Tax [Member]
Operating loss carry-forwards	$ 30,471,000
Operating loss carry-fowards expire term	2018 through 2037
Federal alternative minimum tax credit carryforwards for federal income tax	$ 217,000
Federal Income Tax [Member] | Research and Development Tax Credit Carryforward [Member]
Operating loss carry-fowards expire term	2017 through 2037
Research and development tax credit carryforwards	$ 1,039,000
State Income Tax [Member]
Operating loss carry-forwards	$ 21,547,000
Operating loss carry-fowards expire term	2030 through 2037
State Income Tax [Member] | Research and Development Tax Credit Carryforward [Member]
Operating loss carry-fowards expire term	2023 through 2032
Research and development tax credit carryforwards	$ 207,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current deferred taxes, Inventories	$ 7,856	$ 19,640
Accounts receivable allowance	17,253
Current deferred taxes, Other accruals	33,399	23,714
Current deferred taxes, Less: valuation allowance	(58,508)	(43,354)
Current deferred taxes, Total current deferred tax assets
Long term deferred taxes, Accelerated tax depreciation	14,582	14,134
Long term deferred taxes, Non-cash, stock-based compensation, nonqualified	711,676	562,426
Long term deferred taxes, Impairment loss on investment	146,782
Long term deferred taxes, Goodwill and intangibles
Long term deferred taxes, Operating loss carry forwards and tax credits	13,561,012	12,028,900
Long term deferred taxes, Less: valuation allowance	(14,434,052)	(12,605,460)
Long term deferred taxes, Total long term deferred tax assets (liabilities), net
Long term deferred taxes, Total net deferred tax liabilities

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax (Benefit) Provision Rate (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal tax provision rate	34.00%	34.00%
Permanent differences	24.00%	(12.00%)
State tax expense	0.00%	0.00%
Refundable AMT and R&D tax credit	0.00%	0.00%
Net operating loss carry back	0.00%	0.00%
Valuation allowance	(58.00%)	(23.00%)
Effective income tax provision	0.00%	0.00%

Commitments and Contingencies42

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 29, 2016	Nov. 01, 2014	Apr. 30, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Rental expenses		$ 5,385
Lease expire date		Dec. 30, 2017
BioMolecular Assays, Inc [Member]
Percentage of royalty on sales of products				5.00%
Royalties				$ 6,963	$ 31,301
Percentage of royalty equal of license or other fees and royalties				20.00%
Battelle Memorial Institute [Member]
Minimum annual royalty				$ 3,000	2,000	$ 1,200
Battelle Memorial Institute [Member] | 2017 [Member]
Minimum annual royalty				4,000
Battelle Memorial Institute [Member] | 2018 [Member]
Minimum annual royalty				5,000
Target Discovery Inc [Member]
Minimum annual royalty				$ 20,000	$ 22,000
Monthly fees			$ 1,400
Payment for technical support service per day			$ 2,000
Corporate Office [Member]
Rental expenses	$ 4,800
Lease expire date	Dec. 31, 2017

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 122,220
Thereafter
Total minimum payments required	$ 122,220

Convertible Debt and Other De44

Convertible Debt and Other Debt (Details Narrative) - USD ($)	Oct. 28, 2016	Sep. 15, 2016	Aug. 26, 2016	Aug. 25, 2016	Jul. 29, 2016	Jul. 02, 2016	Jun. 14, 2016	May 24, 2016	May 13, 2016	Feb. 08, 2016	Jan. 20, 2016	Aug. 28, 2015	May 29, 2015	Mar. 17, 2015	Jan. 29, 2015	Jan. 15, 2015	Jun. 06, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 16, 2016	Dec. 06, 2016	Nov. 23, 2016	Nov. 02, 2016	Sep. 30, 2016	Jun. 30, 2016	May 09, 2016	Jan. 06, 2014
Warrants purchase price																		$ 6,325,102	$ 5,416,681
Debt principal amount																		$ 2,509,045
Warrants rights description																		Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTCQB (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days.
Amortized of debt discount																		$ 3,740,746
Fair value of warrant																		2,847,624
Gross proceeds from warrants																		6,329,549
Debt conversion amount																		$ 117,837	$ 396,919
Debt conversion into common stock shares																		(100,000)	(382,054)
Additional convertible debentures																		$ 20,721
Beneficial conversion feature																		(20,721)
Oroginal issue of discount																		740,628	$ 5,223,658
Proceeds from common stock																		530,965
Payments on non-convertible debt																		(947,702)	(587,949)
Borrowed from related parties																		116,667	6,300
Repayment of debt																		107,000	2,653,990
Unamortized debt discount																		2,235,839	0
Investor [Member]
Warrants purchase price																			93,488
Non Realated Parties [Member]
Repayment of debt																			587,949
Other Convertible Notes [Member]
Percentage of annual interest rates		9.00%
Debt conversion price per share		$ 0.45			$ 0.45	$ 0.45		$ 0.45
Issuance of warrants to purchase of common stock shares						34,333		50,000
Warrant exercise price per share								$ 0.55
Amortized of debt discount		$ 45,000			$ 25,518	$ 26,000
Fair value of warrant								$ 12,406
Debt conversion into common stock shares		200,000			32,500	65,000	30,667
Additional convertible debentures		$ 500,000			$ 100,000		$ 115,000	107,000
Beneficial conversion feature					12,759			$ 7,962
Proceeds from pay off outstanding balance of previous loan						$ 85,000
Fair value of convertible note		434,028			87,241
Fair value of common shares					$ 12,759
Oroginal issue of discount		40,541
Proceeds from common stock		$ 65,972
Revolving Note [Member]
Amortized of debt discount																		84,200
Fair value of warrant																		3,125,000
One-time interest amount																		125,000
Fees and commission																		116,500
Unamortized debt discount																		$ 637,030
Revolving Note [Member] | Prior To April 28, 2017 [Member]
Percentage of annual interest rates																		10.00%
Revolving Note [Member] | April 28, 2017 And July 28, 2017 [Member]
Percentage of annual interest rates																		4.00%
Revolving Note [Member] | July 28, 2017 And October 28, 2017 [Member]
Percentage of annual interest rates																		4.00%
Revolving Note [Member] | Investor [Member]
Warrants purchase price																		$ 479,730
Three Ninety-Day Notes [Member] | Investor [Member]
Debt principal amount																			600,000
Proceeds from issuance of private placement																			5,000,000
Accrued interest																			$ 60,000
Related Party Notes [Member]
Advances from related party																		20,000
Individuals [Member]
Borrowed from related parties											$ 50,000
Lender [Member] | Merchant Agreement [Member]
Proceeds from pay off outstanding balance of previous loan			$ 122,645
Fair value of convertible note																								$ 32,430
Collected rate business day			$ 1,386							$ 927
Debenture fee										2,000
Payment of other notes										$ 129,900
Pay off prior loan amount																									$ 48,420
Lender [Member] | Other Convertible Notes [Member]
Debt conversion amount									$ 117,837
Debt conversion into common stock shares									420,849
Other note outstanding balance																		0
Lender [Member] | Other Notes [Member] | Merchant Agreement [Member]
Proceeds from pay off outstanding balance of previous loan																	$ 138,840
Collected rate business day																	1,280
Debenture fee																											$ 2,500
Payment of other notes																	322,500
Gain on settlement of previous loan																	$ 5,044
Lender [Member] | Promissory Note [Member] | Merchant Agreement [Member]
Issuance of warrants to purchase of common stock shares																										100,000
Warrant exercise price per share																										$ 0.55
Amortized of debt discount				$ 6,000
Fair value of warrant				27,349
Debt conversion amount				$ 41,200
Debt conversion into common stock shares				100,049
Repayment of debt				$ 206,000
Loan paid back date				Aug. 25, 2016
Debt maturity date start				Aug. 11, 2016
Debt maturity date ending				Aug. 25, 2016
Board Of Directors [Member] | Other Convertible Notes [Member]
Convertible debentures issued to related parties																		291,000
Placement Agent [Member] | Other Convertible Notes [Member]
Amortized of debt discount																		3,876,622
Fair value of warrant																		2,101,786
Gross proceeds from warrants																		536,908
Convertible debentures issued to related parties																		3,142,078
Deferred finance fees																		$ 621,500
Investor [Member] | Revolving Note [Member]
Percentage of debt original issue discount on purchase price	40.00%
Issuance of warrants to purchase of common stock shares	625,000
Fair value of convertible note	$ 2,000,000
Debt maturity date ending	Oct. 28, 2017
Advance pursuant to revolving note	$ 250,000																			$ 1,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000
Investor [Member] | Revolving Note [Member] | Maximum [Member]
Issuance of warrants to purchase of common stock shares	2,500,000
Advance pursuant to revolving note	$ 500,000
Holder [Member]
Percentage of outstanding principal amount of debenture	5.00%
Gross proceeds of purchase consideration	$ 7,000,000
Equity ownership, percentage	5.00%
Subscription Agreement [Member] | Individuals [Member] | July 23, 2015 and March 31, 2016 [Member]
Percentage of warrants to purchase shares of common stock																		50.00%
Warrants purchase price																		$ 6,329,549
Percentage of debt original issue discount on purchase price																		10.00%
Percentage of annual interest rates																		10.00%
Convertible debentures term																		2 years
Debt conversion price per share																		$ 0.28
Percentage of outstanding principal amount of debenture																		120.00%
Issuance of warrants to purchase of common stock shares																		11,302,766
Warrant exercise price per share																		$ 0.40
Warrants expiration period																		5 years
Merchant Agreement [Member]
Received in exchange for rights to all customer receipts												$ 300,000	$ 100,000	$ 50,000	$ 200,000	$ 150,000
Lender paid												384,000	132,000	67,450	278,000	187,500
Collected rate business day												2,560	1,098	559	1,985	744
Proceeds from outstanding balance of previous loan from lender												131,710				67,925
Debenture fee												$ 6,000	$ 3,999	$ 999	$ 999	$ 1,875
Merchant Agreement [Member] | Lender [Member]
Repayment of debt																		$ 70,000
Merchant Agreement [Member] | Lender [Member] | Other Notes [Member]
Other note outstanding balance																		157,287
Merchant Agreement [Member] | Lender [Member] | Promissory Note [Member]
Other note outstanding balance																		0
Merchant Agreement [Member] | Lender [Member]
Other note outstanding balance																		$ 48,440

Convertible Debt and Other De45

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)		12 Months Ended
		Dec. 31, 2016	Nov. 10, 2014	Jun. 04, 2014	Dec. 04, 2013
Loan Amount		$ 2,509,045
Outstanding Balance			$ 75,000	$ 150,000	$ 223,000
Discount related to Fair value of conversion feature and warrants		(20,721)
Fixed Rate Convertible Notes [Member]
Loan Amount		7,229,549
Outstanding Balance		7,229,549
Original Issue Discount		725,496
Deferred Finance Fees		1,158,408
Discount related to Fair value of conversion feature and warrants		$ 6,060,837
Fixed Rate Convertible Notes [Member] | Convertible Debt [Member]
Inception Date		Jul. 22, 2015
Term		24 months
Loan Amount		$ 2,180,000
Outstanding Balance		2,180,000
Original Issue Discount	[1]	$ 218,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 388,532
Discount related to Fair value of conversion feature and warrants		$ 2,163,074
Fixed Rate Convertible Notes [Member] | Convertible Debt Two [Member]
Inception Date		Sep. 25, 2015
Term		24 months
Loan Amount		$ 1,100,000
Outstanding Balance		1,100,000
Original Issue Discount	[1]	$ 110,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 185,956
Discount related to Fair value of conversion feature and warrants		$ 1,022,052
Fixed Rate Convertible Notes [Member] | Convertible Debt Three [Member]
Inception Date		Oct. 2, 2015
Term		24 months
Loan Amount		$ 150,000
Outstanding Balance		150,000
Original Issue Discount	[1]	$ 15,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 26,345
Discount related to Fair value of conversion feature and warrants		$ 140,832
Fixed Rate Convertible Notes [Member] | Convertible Debt Four [Member]
Inception Date		Oct. 6, 2015
Term		24 months
Loan Amount		$ 30,000
Outstanding Balance		30,000
Original Issue Discount	[1]	$ 3,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 5,168
Discount related to Fair value of conversion feature and warrants		$ 26,721
Fixed Rate Convertible Notes [Member] | Convertible Debt Five [Member]
Inception Date		Oct. 14, 2015
Term		24 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[1]	$ 5,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 8,954
Discount related to Fair value of conversion feature and warrants		$ 49,377
Fixed Rate Convertible Notes [Member] | Convertible Debt Six [Member]
Inception Date		Nov. 2, 2015
Term		24 months
Loan Amount		$ 250,000
Outstanding Balance		250,000
Original Issue Discount	[1]	$ 25,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 43,079
Discount related to Fair value of conversion feature and warrants		$ 222,723
Fixed Rate Convertible Notes [Member] | Convertible Debt Seven [Member]
Inception Date		Nov. 10, 2015
Term		24 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[1]	$ 5,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 8,790
Discount related to Fair value of conversion feature and warrants		$ 46,984
Fixed Rate Convertible Notes [Member] | Convertible Debt Eight [Member]
Inception Date		Nov. 12, 2015
Term		24 months
Loan Amount		$ 215,000
Outstanding Balance		215,000
Original Issue Discount	[1]	$ 21,500
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 38,518
Discount related to Fair value of conversion feature and warrants		$ 212,399
Fixed Rate Convertible Notes [Member] | Convertible Debt Nine [Member]
Inception Date		Nov. 20, 2015
Term		24 months
Loan Amount		$ 200,000
Outstanding Balance		200,000
Original Issue Discount	[1]	$ 20,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 37,185
Discount related to Fair value of conversion feature and warrants		$ 200,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Ten [Member]
Inception Date		Dec. 4, 2015
Term		24 months
Loan Amount		$ 170,000
Outstanding Balance		170,000
Original Issue Discount	[1]	$ 17,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 37,352
Discount related to Fair value of conversion feature and warrants		$ 170,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Eleven [Member]
Inception Date		Dec. 11, 2015
Term		24 months
Loan Amount		$ 360,000
Outstanding Balance		360,000
Original Issue Discount	[1]	$ 36,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 75,449
Discount related to Fair value of conversion feature and warrants		$ 360,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member]
Inception Date		Dec. 18, 2015
Term		24 months
Loan Amount		$ 55,000
Outstanding Balance		55,000
Original Issue Discount	[1]	$ 5,500
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 11,714
Discount related to Fair value of conversion feature and warrants		$ 55,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member]
Inception Date		Dec. 31, 2015
Term		24 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount	[1]	$ 10,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 20,634
Discount related to Fair value of conversion feature and warrants		$ 100,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Fourteen [Member]
Inception Date		Jan. 11, 2016
Term		24 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount	[1]	$ 10,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 24,966
Discount related to Fair value of conversion feature and warrants		$ 80,034
Fixed Rate Convertible Notes [Member] | Convertible Debt Fifteen [Member]
Inception Date		Jan. 20, 2016
Term		24 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[1]	$ 5,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 9,812
Discount related to Fair value of conversion feature and warrants		$ 40,188
Fixed Rate Convertible Notes [Member] | Convertible Debt Sixteen [Member]
Inception Date		Jan. 29, 2016
Term		24 months
Loan Amount		$ 300,000
Outstanding Balance		300,000
Original Issue Discount	[1]	$ 30,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 60,887
Discount related to Fair value of conversion feature and warrants		$ 239,113
Fixed Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member]
Inception Date		Feb. 26, 2016
Term		24 months
Loan Amount		$ 200,000
Outstanding Balance		200,000
Original Issue Discount	[1]	$ 20,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 43,952
Discount related to Fair value of conversion feature and warrants		$ 156,048
Fixed Rate Convertible Notes [Member] | Convertible Debt Eightteen [Member]
Inception Date		Mar. 10, 2016
Term		24 months
Loan Amount		$ 125,000
Outstanding Balance		125,000
Original Issue Discount	[1]	$ 12,500
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 18,260
Discount related to Fair value of conversion feature and warrants		$ 106,740
Fixed Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member]
Inception Date		Mar. 18, 2016
Term		24 months
Loan Amount		$ 360,000
Outstanding Balance		360,000
Original Issue Discount	[1]	$ 36,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 94,992
Discount related to Fair value of conversion feature and warrants		$ 265,008
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty [Member]
Inception Date		Mar. 24, 2016
Term		24 months
Loan Amount		$ 106,667
Outstanding Balance		106,667
Original Issue Discount	[1]	$ 10,667
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 15,427
Discount related to Fair value of conversion feature and warrants		$ 91,240
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member]
Inception Date		Mar. 31, 2016
Term		24 months
Loan Amount		$ 167,882
Outstanding Balance		167,882
Original Issue Discount	[1]	$ 16,788
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 2,436
Discount related to Fair value of conversion feature and warrants		$ 165,446
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member]
Inception Date		Apr. 5, 2016
Term		24 months
Loan Amount		$ 10,000
Outstanding Balance		10,000
Original Issue Discount	[1]	$ 1,000
Interest Rate	[2]	10.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 10,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Three [Member]
Inception Date		May 24, 2016
Term		7 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount		$ 7,000
Interest Rate		0.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 20,368
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Four [Member]
Inception Date		Jun. 15, 2016
Term		6 months
Loan Amount		$ 40,000
Outstanding Balance		40,000
Original Issue Discount
Interest Rate		12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 3,680
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Five [Member]
Inception Date		Jun. 17, 2016
Term		6 months
Loan Amount		$ 40,000
Outstanding Balance		40,000
Original Issue Discount
Interest Rate		12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 3,899
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Six [Member]
Inception Date		Jun. 22, 2016
Term		6 months
Loan Amount		$ 35,000
Outstanding Balance		35,000
Original Issue Discount
Interest Rate		12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 3,373
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Seven [Member]
Inception Date		Jul. 6, 2016
Term		6 months
Loan Amount		$ 85,000
Outstanding Balance		85,000
Original Issue Discount
Interest Rate		12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 15,048
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Eight [Member]
Inception Date		Jul. 29, 2016
Term		6 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount
Interest Rate		12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 25,518
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Nine [Member]
Inception Date		Sep. 15, 2016
Term		8 months
Loan Amount		$ 500,000
Outstanding Balance		500,000
Original Issue Discount		$ 85,541
Interest Rate		9.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 65,972
[1]	The original issue discount is reflected in the first year.
[2]	The annual interest started accruing in the second year.

Convertible Debt and Other De46

Convertible Debt and Other Debt - Summary of Changes in Convertible Debt, Net of Unamortized Discounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Balance at January 1,	$ 277,342
Issuance of convertible debt, face value	2,509,045
Issuance of revolving note payable, face value	1,250,000
Original issued discount	(189,496)
Debt discount from derivative liabilities (embedded conversion option and warrants)	(1,153,817)
Debt discount from beneficial conversion feature	(20,721)
Deferred financing fees	(385,371)
Debt discount related to one-time interest charge	(170,000)
Repayment of convertible debt	$ (107,000)	$ (2,653,990)
Conversion of convertible debt into common stock	(100,000)	(382,054)
Debt discount from shares and warrants issued with the notes	$ (596,867)
Accretion of interest and amortization of debt discount to interest expense	3,960,822
Balance at December 31,	5,273,937	$ 277,342
Less: revolving note payable	612,970
Less: current portion of convertible debt	4,005,702	100,000
Convertible debt, long-term portion	$ 529,742	$ 177,342

Stockholders' (Deficit) (Detail

Stockholders' (Deficit) (Details Narrative) - USD ($)	Dec. 12, 2016	Nov. 16, 2016	Aug. 29, 2016	May 13, 2016	May 06, 2016	Sep. 25, 2015	Aug. 14, 2015	Aug. 13, 2015	Jul. 21, 2015	May 29, 2015	Apr. 17, 2015	Apr. 10, 2015	Mar. 31, 2015	Mar. 18, 2015	Feb. 25, 2015	Feb. 18, 2015	Jan. 14, 2015	Dec. 23, 2014	Nov. 12, 2014	Jun. 30, 2014	Feb. 28, 2014	Feb. 02, 2014	Jan. 30, 2014	Jan. 29, 2014	Dec. 12, 2013	May 20, 2013	Mar. 28, 2013	Feb. 06, 2013	Jan. 04, 2013	Nov. 15, 2012	Jul. 06, 2012	Nov. 11, 2011	Dec. 31, 2013	Apr. 30, 2012	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Apr. 22, 2016	Nov. 29, 2015	Dec. 31, 2014	Nov. 10, 2014	Sep. 22, 2014	Jun. 04, 2014	Apr. 04, 2014	Jan. 31, 2014	Dec. 21, 2013	Dec. 04, 2013	Dec. 28, 2012
Convertible preferred stock, authorized																																			1,000,000		1,000,000	1,000,000
Convertible preferred stock, par value																																			$ 0.01		$ 0.01	$ 0.01
Convertible preferred stock, shares issued																																			1,000,000		1,000,000	1,000,000
Proceeds from warrants issued																																					$ 6,329,549
Adjustment to additional paid in capital related to the beneficial conversion feature																																					$ 20,721
Common stock, shares outstanding under the plan																																			31,728,945		31,728,945	34,798,914			22,588,451
Convertible debt amount																																										$ 75,000		$ 150,000				$ 223,000
Conversion of convertible debt				$ 117,837		$ 30,000		$ 40,000	$ 20,000	$ 35,000	$ 30,000	$ 35,000	$ 27,500	$ 22,500	$ 38,000	$ 25,000	$ 25,000																				$ 145,931	$ 58,919
Conversion of convertible debt, shares				420,849		120,000		160,000	80,000	140,000	120,000	140,000	110,000	90,000	140,741	100,000	100,000																					235,676
Number of common stock shares issued for services																																						1,755,091
Number of common stock value issued for consulting and investor services																																					332,696	$ 457,030
Interest expense																																					$ 4,501,186	$ 4,146,416
Cashless exercise common stock shares issued																																							22,996
Cashless exercise warrants issued																																							70,000
Common stock shares issued																																			30,999,839		30,999,839	23,004,898
Stock Issued During Period, Value, New Issues																																					$ 610,000
Warrents issued																																			$ 6,325,102		$ 6,325,102	$ 5,416,681
Common stock, par value																																			$ 0.01		$ 0.01	$ 0.01
Securities Exchange Agreement [Member] | Everest Investments Holding [Member]
Aggregate number of units sold							601,500
Purchase price per units sold							$ 0.50
Number of restricted common stock purchased							1,000,000
Sale of stock value of shares received							$ 400,000
Investor [Member]
Number of common stock shares issued for services																																						1,755,091
Number of common stock value issued for consulting and investor services																																						$ 457,030
Warrents issued																																						$ 93,488
Lender [Member]
Aggregate number of units sold																																					40,000
Interest expense																																					$ 10,000
Lenders [Member]
Conversion of convertible debt																																				$ 41,200
Conversion of convertible debt, shares																																				100,049
2005 Equity Incentive [Member]
Common stock reserved for stock option plan																																			1,800,000		1,800,000
Common stock, shares outstanding under the plan																																			1,153,750		1,153,750
Common stock, shares available for future grant																																			586,250		586,250
2013 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																									3,000,000
Common stock, shares outstanding under the plan																									2,047,500
Common stock, shares available for future grant																									952,500
2015 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																																								5,000,000
Common stock, shares outstanding under the plan																																								2,068,000
Common stock, shares available for future grant																																								2,932,000
Weighted average grant date fair value of options issued																																					$ 0.27
Unrecognized compensation cost																																					$ 369,224
Compensation cost reorganization period																																					1 year 9 months 22 days
Restricted Common Stock [Member]
Number of common stock shares issued for services																																					755,000
Number of common stock value issued for consulting and investor services																																					$ 332,696
Extension One [Member]
Debenture fee																																			$ 13,000		13,000
Extension Two [Member]
Debenture fee																																			13,000		13,000
Extension Three [Member]
Debenture fee																																			10,000		10,000
Extension Four [Member]
Debenture fee																																			$ 8,000		$ 8,000
Five Tranches [Member]
Stock issuance price per share																																			$ 0.40		$ 0.40
Stock Issued During Period, Shares, New Issues																																			1,525,000
Stock Issued During Period, Value, New Issues																																			$ 610,000
Common stock, par value																																			$ 0.01		0.01
Five Tranches [Member] | Investor [Member]
Issuance of warrants to purchase of common stock shares																																			1,525,000
Warrants exercise price per share																																			$ 0.50		$ 0.50
Warrent term																																			5 years
Payments of stock issuance costs																																			$ 79,035
Series D Convertible Preferred Stock [Member]
Proceeds from convertible preferred stock																																					$ 559,275
Additional paid in capital and accumulated deficit																																					530,140
Adjustment to additional paid in capital related to the beneficial conversion feature																																					$ 530,140
Convertible preferred stock, conversion percentage																																					300.00%
Subsequent financing pro-rata basis percentage																																					50.00%
Series D Warrant [Member]
Warrants exercise price per share																																	$ 0.25	$ 0.40	$ 0.81		$ 0.81
Change in number of warrants																																	628,733	530,406
Number of warrants issued during period																																	1,676,608	1,047,875
Series D Warrant [Member] | Merger Or Consolidation [Member]
Percentage of stock acquired																																					50.00%
Series G Warrant [Member]
Warrants exercise price per share																																			0.50		$ 0.50
Warrants expiration date																																					Jul. 6, 2015
Change in exercise price of warrants																																			0.60		$ 0.60
Series J Warrant [Member]
Warrants exercise price per share																																			$ 0.40		$ 0.40
Series J Warrant [Member] | Minimum [Member]
Change in number of warrants																																					5,000,000
Series K Warrant [Member]
Proceeds from direct offering																						$ 5,000,000
Warrants exercise price per share																			$ 0.3125	$ 0.375	$ 0.425			$ 0.3125																							$ 0.3125
Warrant Derivative Liability [Member]
Proceeds from direct offering																																					$ 283,725
Weighted average grant date fair value of options issued																																					$ 0.40	$ 0.40
Aggregate warrant to lenders to purchase commno stock shares																																					8,767,857	2,517,052
Aggregate warrant to placement agent to purchase common stock shares																																					1,689,286	412,500
Warrant expiring term																																					5 years	5 years
Incremental value of warrant extension																																						$ 69,627
Convertible Debt [Member] | Lenders [Member]
Conversion of convertible debt, shares																																				297,500
Series A Junior Participating Preferred Stock [Member]
Number of stock designated																																			20,000		20,000
Series A Convertible Preferred Stock [Member]
Number of stock designated																																			313,960		313,960
Series B Convertible Preferred Stock [Member]
Number of stock designated																																			279,256		279,256
Series C Convertible Preferred Stock [Member]
Number of stock designated																																			88,098		88,098
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																																			850		850	850
Convertible preferred stock, par value																																$ 0.01			$ .01		$ .01	$ .01
Convertible preferred stock, shares issued																																			300		300	300
Number of stock designated																																			850		850
Preferred stock shares outstanding																																			300		300	300
Aggregate number of units sold																																843
Purchase price per units sold																																$ 1,000
Proceeds from direct offering																																$ 843,000
Issuance of warrants to purchase of common stock shares																																614
Warrants exercise price per share																																$ 0.81
Amount to be paid at any uncertain situation value per share (subject to accrued but unpaid dividends)																																			$ 1,000		$ 1,000
Preferred stock value issued																																			$ 3		$ 3	$ 3
Change in exercise price of warrants																																			$ 0.65		$ 0.65
Series D Convertible Preferred Stock [Member] | Merger Or Consolidation [Member]
Proceeds from convertible preferred stock																																					$ 50,000
Percentage of stock acquired																																					50.00%
Series D Convertible Preferred Stock [Member] | Series D Warrant [Member]
Proceeds from warrants issued																																					$ 283,725
Series E Convertible Preferred Stock [Member]
Number of stock designated																																			500		500
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																																			240,000		240,000	240,000
Convertible preferred stock, par value																															$ 0.01				$ 0.01		$ 0.01	$ 0.01
Convertible preferred stock, shares issued																																			86,570		86,570	86,570
Number of stock designated																																			240,000		240,000
Preferred stock shares outstanding																																			86,570		86,570	86,570
Aggregate number of units sold																														145,320	145,320
Purchase price per units sold																														$ 5	$ 5
Proceeds from direct offering																														$ 726,600	$ 726,600
Issuance of warrants to purchase of common stock shares																																					5
Warrants exercise price per share																															$ 0.50				$ 0.50		$ 0.50
Convertible preferred stock, conversion percentage																																					12.00%
Percentage of shares purchased for investment																																					6.00%
Value of shares invested in private placements																																					$ 726,600
Cumulative dividend rate percentage																																					4.00%
Preferred stock value issued																																			$ 866		$ 866	$ 866
Stock issuance price per share																																			$ 0.75		$ 0.75
Warrant expiring term																															3 years
Series G Convertible Preferred Stock [Member] | Minimum [Member]
Proceeds from direct offering																																					$ 2,500,000
Value of shares invested in private placements																																					250,000
Preferred stock value issued																																			$ 100,000		$ 100,000
Average daily trading volume																																					10,000
Series G Convertible Preferred Stock [Member] | Maximum [Member]
Preferred stock value issued																																			$ 250,000		$ 250,000
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																																			10,000		10,000	10,000											10,000
Convertible preferred stock, par value																													$ 0.01						$ 0.01		$ 0.01	$ 0.01
Convertible preferred stock, shares issued																																			10,000		10,000	10,000
Number of stock designated																																			10,000		10,000
Preferred stock shares outstanding																																			10,000		10,000	10,000
Purchase price per units sold																													$ 0.8025
Issuance of warrants to purchase of common stock shares																													100
Preferred stock value issued																																			$ 100		$ 100	$ 100
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																																			21		21	21
Convertible preferred stock, par value																		$ 0.01																	$ 0.01		$ 0.01	$ 0.01
Convertible preferred stock, shares issued																		21																	21		21	21
Number of stock designated																																			21		21
Preferred stock shares outstanding																																			21		21	21
Purchase price per units sold																		$ 0.25
Issuance of warrants to purchase of common stock shares																		100,000
Preferred stock value issued
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																																			6,250		6,250	6,250
Convertible preferred stock, par value																										$ 0.01	$ 0.01	$ 0.01							$ 0.01		$ 0.01	$ 0.01
Convertible preferred stock, shares issued																																			3,521		3,521	3,546
Number of stock designated																																			6,250		6,250
Preferred stock shares outstanding																																			3,521		3,521	3,546
Aggregate number of units sold																										5,087.5	5,087.5	5,087.5
Purchase price per units sold																										$ 400	$ 400	$ 400
Proceeds from direct offering																										$ 2,034,700	$ 2,034,700	$ 2,034,700									$ 2,500,000
Convertible preferred stock, shares outstanding			25
Issuance of warrants to purchase of common stock shares																																					1,000
Warrants exercise price per share																																			$ 0.40		$ 0.40
Convertible preferred stock, conversion percentage																																					4.00%
Percentage of stock acquired																																					6.00%
Value of shares invested in private placements																												250,000									$ 2,034,700
Preferred stock value issued																												$ 250,000							$ 35		$ 35	$ 36
Stock issuance price per share																																			$ 0.80		$ 0.80
Warrants expiration term																																					P3Y
Common stock shares issued			1,112
Accrued dividend			$ 442
Convertible preferred stock common stock shares issued			25,000
Series J Convertible Preferred Stock [Member] | Minimum [Member]
Value of shares invested in private placements																																					$ 2,500,000
Stock issuance price per share																																			$ 0.80		$ 0.80
Average daily trading volume																																					50,000
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																																			15,000		15,000	15,000
Convertible preferred stock, par value																			$ 0.01	$ 0.01	$ 0.01			$ 0.01											$ 0.01		$ 0.01	$ 0.01
Convertible preferred stock, shares issued																			1,000	1,000	1,000			1,000											6,816		6,816	11,416					64,000
Number of stock designated																																			15,000		15,000
Preferred stock shares outstanding					4,600																														6,816		6,816	11,416
Aggregate number of units sold																			1,052	734	1,854			4,875	4,000
Purchase price per units sold																			$ 250	$ 300	$ 340			$ 250	$ 250
Proceeds from direct offering																			$ 263,000	$ 220,000	$ 630,360		$ 1,500,000	$ 1,218,750	$ 1,000,000												$ 100,000
Issuance of warrants to purchase of common stock shares																			500	500	500			500													1,000
Warrants exercise price per share																			$ 0.3125	$ 0.375	$ 0.425														$ 0.3125		$ 0.3125
Proceeds from warrants issued																																					$ 271,422
Proceeds from convertible preferred stock																																					685,245
Adjustment to additional paid in capital related to the beneficial conversion feature																																					$ 1,495,415
Convertible preferred stock, conversion percentage																																					4.00%
Percentage of stock acquired																																					6.00%
Number of warrants issued during period																																					500
Value of shares invested in private placements																			$ 3,332,110																		$ 1,000,000
Cash received in private placement																			2,511,404																		572,044
Conversion of outstanding indebtedness and accrued board of directors' fees																			$ 820,706																$ 427,956		427,956
Preferred stock value issued																																			$ 68		$ 68	$ 114
Stock issuance price per share																																			$ 0.80		$ 0.80
Average daily trading volume																																					50,000
Warrants expiration date																			Nov. 12, 2017	Jun. 30, 2017	Feb. 28, 2017			Jan. 29, 2017
Fee incurred with private placement																																					$ 43,334
Increase in subscription amount																					$ 3,500,000			$ 718,750
Common stock shares issued					247,435
Accrued dividend					$ 63,413
Series K Convertible Preferred Stock [Member] | Tranche Two [Member]
Proceeds from direct offering																								$ 1,500,000
Increase in subscription amount																																														$ 1,218,750
Series K Convertible Preferred Stock [Member] | Tranche Third [Member]
Proceeds from direct offering																					1,500,000
Increase in subscription amount																					$ 630,360
Series K Convertible Preferred Stock [Member] | Fourth Tranche [Member]
Proceeds from direct offering																				$ 1,500,000
Increase in subscription amount																				$ 220,000
Series K Convertible Preferred Stock [Member] | Fifth Tranche [Member]
Proceeds from direct offering																			$ 1,500,000
Increase in subscription amount																			$ 263,000
Series K Convertible Preferred Stock [Member] | Initial Tranche [Member]
Increase in subscription amount																									$ 1,000,000
Series K Convertible Preferred Stock [Member] | Minimum [Member]
Proceeds from direct offering	$ 2,500,000
Increase in subscription amount																																													$ 4,500,000
Series K Convertible Preferred Stock [Member] | Maximum [Member]
Increase in subscription amount																																													$ 1,000,000
Restricted Common Stock [Member] | Investor [Member]
Number of common stock shares issued for services		330,000
Number of common stock value issued for consulting and investor services		$ 84,735
Stock Issued During Period, Shares, New Issues																																						300,000

Stockholders' (Deficit) - Sched

Stockholders' (Deficit) - Schedule of Assumption Used (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Nov. 10, 2011
Fair value per warrant		$ 0.54
Series K Warrants December 12, 2013 [Member]
Contractual life (in months)	36 months
Expected volatility	136.10%
Risk-free interest rate	0.39%
Exercise price	$ 0.3125
Fair value per warrant	$ 0.20
Series K Warrants January 29, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	152.40%
Risk-free interest rate	0.39%
Exercise price	$ 0.3125
Fair value per warrant	$ 0.30
Series K Warrants February 28, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	152.70%
Risk-free interest rate	0.39%
Exercise price	$ 0.425
Fair value per warrant	$ 0.37
Series K Warrants June 30, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	153.90%
Risk-free interest rate	90.00%
Exercise price	$ 0.375
Fair value per warrant	$ 0.29
Series K Warrants November 12, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	153.90%
Risk-free interest rate	90.00%
Exercise price	$ 0.3125
Fair value per warrant	$ 0.23

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Shares, Beginning balance	34,798,914	22,588,451
Shares, Granted	8,179,552	13,337,141
Shares, Exercised	(70,000)
Shares, Expired	(11,063,521)	(996,678)
Shares, Forfeited	(116,000)	(130,000)
Shares, Ending balance	31,728,945	34,798,914
Exercisable, Beginning balance	31,664,469	20,858,111
Exercisable, Ending balance	29,730,959	31,664,469
Stock Option [Member]
Shares, Beginning balance	5,571,250	3,406,250
Shares, Granted		2,500,000
Shares, Exercised
Shares, Expired	186,000	(205,000)
Shares, Forfeited	116,000	(130,000)
Shares, Ending balance	5,269,250	5,571,250
Weighted average price per share, Beginning balance	$ 0.44	$ 0.51
Weighted average price per share, Granted		0.40
Weighted average price per share, Exercised
Weighted average price per share, Expired	1	1
Weighted average price per share, Forfeited	0.51	0.70
Weighted average price per share, Ending balance	$ 0.42	$ 0.44
Warrants [Member]
Shares, Beginning balance	29,227,664	19,182,201
Shares, Granted	8,179,552	10,837,141
Shares, Exercised	(70,000)
Shares, Expired	(10,877,521)	(791,678)
Shares, Forfeited
Shares, Ending balance	26,459,695	29,227,664
Weighted average price per share, Beginning balance	$ 0.44	$ 0.49
Weighted average price per share, Granted	0.42	0.40
Weighted average price per share, Exercised	0.31
Weighted average price per share, Expired	0.55	0.31
Weighted average price per share, Forfeited
Weighted average price per share, Ending balance	$ 0.40	$ 0.44

Stockholders' Deficit - Sched50

Stockholders' Deficit - Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Exercise Price 1 [Member]
Exercise price range, lower range limit	$ 0.30
Exercise price range, upper range limit	$ 0.39
Options outstanding, number of options | shares	1,625,500
Options outstanding, weighted average remaining contractual life	7 years 8 months 12 days
Options outstanding, weighted average exercise price	$ 0.30
Options exercisable, number of options | shares	1,342,762
Options exercisable, weighted average remaining contractual life	7 years 8 months 12 days
Options exercisable, weighted average exercise price	$ 0.30
Exercise Price 2 [Member]
Exercise price range, lower range limit	0.40
Exercise price range, upper range limit	$ 0.49
Options outstanding, number of options | shares	2,786,000
Options outstanding, weighted average remaining contractual life	8 years 8 months 12 days
Options outstanding, weighted average exercise price	$ 0.40
Options exercisable, number of options | shares	1,454,665
Options exercisable, weighted average remaining contractual life	8 years 4 months 24 days
Options exercisable, weighted average exercise price	$ 0.40
Exercise Price 3 [Member]
Exercise price range, lower range limit	0.50
Exercise price range, upper range limit	$ 0.59
Options outstanding, number of options | shares	226,250
Options outstanding, weighted average remaining contractual life	5 years 7 months 6 days
Options outstanding, weighted average exercise price	$ 0.50
Options exercisable, number of options | shares	226,250
Options exercisable, weighted average remaining contractual life	5 years 7 months 6 days
Options exercisable, weighted average exercise price	$ 0.50
Exercise Price 4 [Member]
Exercise price range, lower range limit	0.60
Exercise price range, upper range limit	$ 0.69
Options outstanding, number of options | shares	385,500
Options outstanding, weighted average remaining contractual life	3 years 1 month 6 days
Options outstanding, weighted average exercise price	$ 0.60
Options exercisable, number of options | shares	385,500
Options exercisable, weighted average remaining contractual life	3 years 1 month 6 days
Options exercisable, weighted average exercise price	$ 0.60
Exercise Price 5 [Member]
Exercise price range, lower range limit	0.70
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	246,000
Options outstanding, weighted average remaining contractual life	2 years 3 months 18 days
Options outstanding, weighted average exercise price	$ 1
Options exercisable, number of options | shares	246,000
Options exercisable, weighted average remaining contractual life	2 years 3 months 18 days
Options exercisable, weighted average exercise price	$ 1
Exercise Price 6 [Member]
Exercise price range, lower range limit	0.30
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	5,269,250
Options outstanding, weighted average remaining contractual life	7 years 7 months 6 days
Options outstanding, weighted average exercise price	$ 0.42
Options exercisable, number of options | shares	3,655,177
Options exercisable, weighted average remaining contractual life	7 years 1 month 6 days
Options exercisable, weighted average exercise price	$ 0.43

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

Mar. 21, 2017USD ($)shares

Mar. 16, 2017$ / sharesshares

Mar. 14, 2017USD ($)shares

Mar. 02, 2017USD ($)

Feb. 15, 2017USD ($)shares

Feb. 06, 2017USD ($)

Jan. 31, 2017USD ($)

Jan. 17, 2017USD ($)Integer$ / sharesshares

Jan. 06, 2017USD ($)shares

Aug. 28, 2015USD ($)

May 29, 2015USD ($)

Mar. 17, 2015USD ($)

Jan. 29, 2015USD ($)

Jan. 15, 2015USD ($)

Feb. 28, 2017USD ($)shares

Jan. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Proceeds from convertible debt

$ 2,105,420

$ 5,558,537

Merchant Agreement [Member]

Debt instrument, monthly allotments

$ 2,560

$ 1,098

$ 559

$ 1,985

$ 744

Subsequent Event [Member]

Number of restricted common stock issued, shares | shares

50,000

Payment of debt

$ 34,000

Number of restricted common stock issued

$ 10,000

Debt instrument, monthly allotments

$ 25,000

Number of allotments | Integer

3

Subsequent Event [Member] | Months 1-3 [Member]

Warrant exercise price | $ / shares

$ 0.40

Number of warrants issued | shares

100,000

Subsequent Event [Member] | Months 4-6 [Member]

Warrant exercise price | $ / shares

$ 0.60

Number of warrants issued | shares

125,000

Subsequent Event [Member] | Months 7-9 [Member]

Warrant exercise price | $ / shares

$ 0.80

Number of warrants issued | shares

125,000

Subsequent Event [Member] | Months 10-12 [Member]

Warrant exercise price | $ / shares

$ 1

Number of warrants issued | shares

150,000

Subsequent Event [Member] | October Revolving Note [Member]

Proceeds from loan

$ 500,000

$ 250,000

Number of warrants to purchase common stock | shares

1,875,000

Subsequent Event [Member] | Merchant Agreement [Member]

Proceeds from loan

$ 75,000

$ 125,000

Fee paid for loan

1,250

Payment of debt

$ 16,180

Subsequent Event [Member] | Privately-Held Investment Firm [Member]

Loan interest rate

10.00%

Original issue of discount percentage

10.00%

Number of restricted common stock issued, shares | shares

250,000

Subsequent Event [Member] | Privately-Held Investment Firm [Member] | Non Convertible Loan [Member]

Proceeds from convertible debt

$ 250,000

Subsequent Event [Member] | Two Accredited Investors [Member]

Loan interest rate

10.00%

Number of restricted common stock issued, shares | shares

170,000

Subsequent Event [Member] | Two Accredited Investors [Member] | Non Convertible Loan [Member]

Proceeds from convertible debt

$ 110,000

Subsequent Event [Member] | Incentive Stock Options [Member] | Employees [Member]

Common stock, shares available for future grant to employees | shares

660,000

Stock option exercise price | $ / shares

$ 0.28

Stock option expected term

10 years

Subsequent Event [Member] | Incentive Stock Options [Member] | Officers, Consultants and Directors [Member]

Common stock, shares available for future grant to employees | shares

1,855,000

Subsequent Event [Member] | Restricted Stock [Member]

Warrant exercise price | $ / shares

$ 0.40

Subsequent Event [Member] | Accredited Investor [Member]

Proceeds from non convertible debt

$ 170,000

Loan interest rate

10.00%

Original issue of discount percentage

10.00%

Number of restricted common stock issued, shares | shares

170,000